See this page online at: http://www.bioscienceworld.ca/Deals
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
February 17 2011
Dealmakers Miraculins Inc. (Winnipeg, MB) preeclampsia program is being advanced in partnership with Alere, Inc., (Waltham, MA) one of the world’s largest diagnostic companies
|
|
November 22 2010
Economic strategy team tackles challenges facing Ontario’s future Thought leaders from every facet of Ontario’s health-science sector and all regions of the province, working together on the Ontario Bioscience Economic Strategy Team (OBEST™), announce the initial phase of an evergreen strategy for sustainability of the province’s health-sciences industry.
|
|
October 14 2010
Labopharm and Paladin announce expansion of commercial relationship Labopharm Inc. and Paladin Labs Inc. expand its commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions.
|
|
September 27 2010
Pharmacist prescribing interest high The pharmacy practice continues to change as prescribing authorization shifts further in favour of pharmacists across Canada. Pharmacists in BC and Alberta are still exercising a high level of prescribing freedom, those in New Brunswick and Newfoundland & Labrador are enjoying their new prescribing rights, and Ontario and Saskatchewan are awaiting recently passed legislation to take effect.
|
|
September 14 2010
Miraculins completes PREVU Skin Cholesterol Test acquisition Miraculins Inc. completes the acquisition from PreMD Inc. of all assets relating to the PREVU(i) Skin Cholesterol Test. PREVU(i) is a simple, non-invasive, inexpensive test that addresses the major worldwide market of cardiovascular risk assessment. PREVU(i) has been cleared for sale in the US by the FDA (Food and Drug Administration). It has also received regulatory clearance for sale in Canada and Europe and was successfully test marketed in the US and Canada.
|
|
August 27 2010
Three Toronto high-tech companies receive seed funding A locally administered treatment for ovarian cancer, software that helps doctors chose the appropriate medical imaging tests and a continuity computing service that keeps businesses running in the face of system failure are the technological innovations coming from three Toronto-based high-tech companies.
|
|
June 03 2010
CDRD and Vancouver Prostate Centre sign collaboration agreement The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.
|
|
April 21 2010
YM BioSciences closes US$17.5 million financing YM BioSciences Inc. announces it has closed its previously announced “registered direct” offering of 14,583,000 million units at an issue price of US $1.20 for gross proceeds of approximately US $17.5 million.
|
|
April 21 2010
Intrinsik announces acquisition of Carexa Inc. Intrinsik Health Sciences Inc. (Intrinsik), a leading provider of toxicology, product development and regulatory affairs consulting services announces it has acquired Carexa Incorporated (Carexa), a regulatory affairs consulting firm which currently does business in North America and Europe.
|
|
April 21 2010
Dealmakers SNC-Lavalin (Montreal, QC) has been awarded a contract by Sasol Nitro (South Africa) to provide engineering, procurement and construction management services.
Dalton Pharma Services (Toronto, ON) announces the renewal of its chemistry services agreement with Boehringer Ingelheim (Canada) Ltd. (Burlington, ON). Lignol Energy Corporation (Burnaby, BC), a technology company in the cellulosic ethanol and biorefining sector, and Kingspan Group PLC , a global supplier of construction products, have reached a joint development agreement. IntelGenx Corp. (Ville St-Laurent, QC) and Cannasat Therapeutics Inc. (Toronto, ON) have signed a letter of intent (LOI). |
|
April 21 2010
Trillium and UHN team up to help patients Trillium Therapeutics Inc. has entered into two definitive license agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids) in Toronto, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.
|
|
April 20 2010
Dealmakers Novozymes (Saskatoon, SK) and ProMetic Life Sciences Inc. (Mount-Royal, QC) have entered into an alliance.
Therapure Biopharma Inc. (Mississauga, ON) and LFB Biomedicaments, a wholly owned subsidary of LFB S.A. YM BioSciences Inc. (Mississauga, ON) has concluded a merger of Cytopia Limited |
|
April 16 2010
Ontario helps Merck and leading research institutions fight cancer Despite some recent improvements in chemotherapy, patients urgently need more effective cancer medications. That is why Ontario is joining forces with Merck and leading research institutions to develop new drugs to fight cancer.
|
|
February 16 2010
MaRS Innovation and CDRD Announce Strategic Collaboration MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries.
|
|
January 26 2010
Dealmakers Ambrilia Biopharma Inc. (Verdun, QC) has extended its exclusive license option agreement with ZBx Corporation (Toronto, ON)
ProMetic Life Sciences Inc. (Mount-Royal, QC) announces the signing of an agreement by ProMetic’s UK subsidiary CardioComm Solutions, Inc. (Victoria, BC) has signed a software development agreement with MD Primer Inc. (Toronto, ON) |
|
January 22 2010
Therapure Biopharma and Stellar Pharmaceuticals announce contract Therapure Biopharma Inc. and Stellar Pharmaceuticals Inc. have reached an agreement under which Therapure will provide fill/finish services for pre-filled syringes of Stellar’s natural viscosupplement, NeoVisc®.
|
|
January 19 2010
Trillium and Biogen Idec enter into global license agreement Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, has entered into a definitive license agreement with Biogen Idec granting the latter exclusive worldwide rights to one of Trillium's development programs.
|
|
December 18 2009
YM BioSciences Inc. and Therapure Biopharma Inc. announce contract David Allan, chairman and CEO of YM BioSciences Inc. and Thomas Wellner, president and CEO of Therapure Biopharma Inc. announce the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
|
|
December 15 2009
Pfizer and B.C. launch $9M collaboration to tackle cancer Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer.
|
|
December 03 2009
Dealmakers QLT (Vancouver, BC) has sold its subsidiary QLT USA to Tolmar Holdings
Octapharma (Lachen, CH) is providing a $4.5 M advance to ProMetic (Mount-Royal, QC) Quest PharmaTech Inc. (Edmonton, AB) has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (St. Laurent, QC) Labopharm Inc. (Montreal, QC) announces that its wholly owned subsidiary, Labopharm Europe Limited, has completed a distribution and supply agreement |
|
December 03 2009
ProMetic signs long-term supply agreement with major global pharmaceutical company ProMetic Life Sciences Inc. has signed a long-term supply agreement with a major global pharmaceutical company for a Mimetic Ligand™ affinity adsorbent developed and manufactured by ProMetic’s UK subsidiary, ProMetic Biosciences Ltd.
|
|
December 03 2009
Carmichael strengthens its portfolio with purchase of Pipette Pro Carmichael Engineering, a leading service provider to the Canadian scientific community is pleased to announce the purchase of Pipette Pro Inc. Since its inception in 1998, Pipette Pro has developed a strong reputation for quality maintenance, repair and calibration of most brands of laboratory pipettes.
|
|
November 06 2009
Microbix and Hunan Biopharmaceutical to build Asia's largest influenza vaccine facility Canadian biotech company will provide its VIRUSMAX™ technology that will double influenza vaccine production.
|
|
October 19 2009
Afexa agrees to pay $7.1 million settlement to shareholders After three years of bad news and plunging share prices, Afexa Life Sciences Inc. has agreed to settle with its shareholders.
|
|
October 19 2009
Bayer inks licensing agreement with Performance Plants Performance Plants Inc. has signed a deal with Bayer CropScience AG, allowing Bayer to develop drought tolerant cotton using their Yield Protection Technology®.
|
|
October 19 2009
Warnex finds distributor for H1N1 test Warnex Inc. has signed a distribution agreement with Biron-Laboratoire medical, provider of diagnostic and medical treatment services. Under the terms of the agreement, Biron will promote and distribute Warnex’s H1N1 influenza test kit, specifically targeting industrial companies.
|
|
October 19 2009
Stellar gains expected after stellar company retained Stellar Pharmaceuticals Inc. has retained the services of Kilmer Lucas, experts in cross-border investor relations and corporate communications.
|
|
October 19 2009
Dealmakers Monsanto Canada (Winnipeg, MB) has filled two key positions on its leadership team.
In a signed letter of intent Medicago Inc. (Québec City, QC) officially began a collaboration with Tabuk Pharmaceuticals. Lab Research Inc. (Laval, QC) has entered into three separate agreements. Former executive vice president, Operations & Human Resources Peter Graham has been appointed president and CEO of CCR Technologies Ltd. (Calgary, AB) Kane Biotech Inc. (Winnipeg, MB) has entered into a cooperative research and development agreement |
|
September 10 2009
Company begins metamorphosis through new subsidiary and licence agreement Syngar Technologies Inc., a new subsidiary of Cyplasin Biomedical Ltd., has entered into a licence agreement for the enhanced production of biofuels using their new PLUS Wave™ technology.
|
|
September 10 2009
Chemaphor assembles third party advisory team A third party, business and technology advisory team has been established by Chemaphor.
|
|
September 10 2009
Upstream Biosciences Inc. begins restructuring process Upstream Biosciences Inc. announces that it is offering license or acquisition opportunities for some of its assets in order to restructure the company.
|
|
September 10 2009
Securities investigation concludes with settlement An Alberta Securities Commission investigation into Afexa Life Sciences Inc. financial dealings has ended in settlement.
|
|
September 10 2009
Bioniche Life Science Inc. (Belleville, ON) announces that Endo Pharmaceuticals Inc. (Chadds Ford, PA) has obtained the exclusive rights to develop and market Urocidin™, Bioniche’s new treatment for non-muscle-invasive bladder cancer.
|
|
September 10 2009
LabVantage (Bridgewater, NJ) announces it has completed the acquisition of Life Technologies Corporation’s (Carlsbad, CA) laboratory information management system unit.
|
|
September 10 2009
ImmunoVaccine Technologies Inc. A partnership agreement has been reached between ImmunoVaccine Technologies Inc. (Halifax, NS) and Scancell Ltd. (Nottingham, UK)
|
|
September 10 2009
Fielding Chemical Technologies Inc. (Mississauga, ON) together with Phancorp Inc. (Brampton, ON) will merge, to provide customers “cradle to cradle®” care of chemicals, the company’s presidents said.
|
|
September 03 2009
Medicago to collaborate with Tabuk for commercial development of influenza vaccines in Saudi Arabia and other territories Medicago Inc. has signed a Letter of Intent (LOI) with Tabuk Pharmaceuticals to develop, produce and commercialize Medicago's influenza VLP-based vaccines in Saudi Arabia and other territories in the Middle East and North Africa.
|
|
August 18 2009
Vasogen and IntelliPharmaCeutics combine to create specialty pharmaceutical company Vasogen Inc. and IntelliPharmaCeutics (IPC) have entered into a definitive agreement, subject to shareholder and regulatory approvals, whereby Vasogen will combine with IPC under a plan of arrangement and merger to continue as a publicly-traded entity to be called IntelliPharmaCeutics International Ltd.
|
|
July 14 2009
Amerisource Bergen Corp buys Canadian pharma service provider Pharmaceutical wholesaler AmerisourceBergen Corp. has purchased Innomar Strategies Inc., a Canadian specialty pharmaceutical services company, for about $15 million Canadian.
|
|
July 14 2009
Dealmakers Paladin Labs Inc. (St. Laurent, QC) announces that it has closed its previously announced bought deal.
Warnex Inc. (Laval, QC) concludes the acquisition of all of the issued and outstanding shares of Molecular World Inc. Xenon Pharmaceuticals Inc. (Burnaby, BC) has formed an alliance with Merck & Co., Inc. Viterra Inc. (Regina, SK) announces it has acquired the assets of Associated Proteins LP. |
|
July 14 2009
Ambrilia reaches settlement with Merck Ambrilia has reached a settlement with Merck Sharp and Dohme Research Ltd. and Merck & Co. the arbitration pending before the International Court of Arbitration of the International Chamber of Commerce concerning its exclusive License Agreement of October 12, 2006 and a November 14, 2003 Confidentiality Agreement (the “Arbitration”).
|
|
July 14 2009
Amorfix licenses theranostic platform Amorfix Life Sciences has licensed the exclusive rights to the ProMIS ™ target identification technology from the University of British Columbia (UBC), to predict novel Disease Specific Epitopes (DSE) on the molecular surface of misfolded proteins.
|
|
July 14 2009
Med BioGene closes first tranche of private placement Med BioGene Inc. has closed the first tranche of its previously announced non-brokered private placement through the issuance of 15,423,488 units for gross proceeds of $1,233,879.
|
|
July 14 2009
Dow AgroSciences renews strategic alliance with NRC in plant biotechnology Dow AgroSciences Canada Inc. announces it has renewed its strategic alliance with the National Research Council Plant Biotechnology Institute (NRC-PBI) of Saskatoon for an additional five-year term.
|
|
July 10 2009
MaRS Innovation selects umbilical cord stem cell technology for commercialization MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital have entered into an agreement to work together on the commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.
|
|
July 01 2009
OncoGenex Pharmaceuticals Added to Russell Indexes Oncogenex, a Vancouver-based biopharmaceutical company announces it has been added to the Russell 3000 Index on June 26.
|
|
July 01 2009
MaRS Innovation selects diabetic wound healing technology as its second commercialization opportunity MaRS Innovation and the University of Toronto are teaming up to commercialize a new sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
|
|
June 29 2009
AEterna Zentaris’ institutional investors offer up US$10 million AEterna Zentaris announces it has completed its previously announced registered direct offering of US$10 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
|
|
June 29 2009
Viterra concludes purchase of canola crush operation Viterra Inc. announces it has closed the purchase of the assets of Associated Proteins LP in Ste. Agathe, Manitoba.
|
|
June 18 2009
LifeSciences British Columbia expands global reach with MOU with Korea's GyeongGi Bio-Center LifeSciences British Columbia enters into a Memorandum of Understanding with the GyeongGi Bio-Center, a non-profit organization responsible for supporting the biotech and pharmaceutical industries in Korea’s GyeongGi Province.
|
|
June 18 2009
AVAC Ltd. appoints new chairman to board of directors Ross Bricker, president and CEO of AVAC Ltd. announces that Art Froehlich has been appointed to the position of chairman of AVAC’s board of directors.
|
|
June 12 2009
New development fund to accelerate commercialization of genomics-related drug discoveries Genome British Columbia and the Centre for Drug Research and Development (CDRD) announce a development fund that offers BC’s researchers another avenue to move promising research along the commercialization path.
|
|
June 12 2009
Paladin announces closing of $58.7 million bought deal financing Paladin Labs Inc. closes its previously announced bought deal offering of 3,450,000 common shares which includes 450,000 common shares issued by way of the underwriters' over-allotment option.
|
|
June 11 2009
The Quebec Consortium for Drug Discovery announces investment of close to $8 million Four projects have been selected from the first competition on drug discovery launched by the Quebec Consortium for Drug Discovery (CQDM) in the fall of 2008. All research proposals have been evaluated through an exhaustive due diligence process involving, among others, an independent scientific and industrial expert panel led by the Fonds de recherche en santé du Québec (FRSQ).
|
|
June 11 2009
Ambrilia settles arbitration with Merck Ambrilia has settled with Merck Sharp and Dohme Research Limited and Merck & Co. the arbitration pending before the International Court of Arbitration of the International Chamber of Commerce that concerned their Exclusive License Agreement of October 12, 2006 and a November 14, 2003 Confidentiality Agreement.
|
|
June 11 2009
Med BioGene announces closing of first trance of private placement Med BioGene Inc. closes the first tranche of its previously announced non-brokered private placement through the issuance of 15,423,488 units for gross proceeds of $1,233,879.
|
|
June 05 2009
Federal government invests in S&T collaboration with Mohawk College Residents of the Golden Horseshoe will profit from the creation of new, highly skilled jobs in the Hamilton area that will bring numerous benefits to the local economy.
|
|
June 05 2009
Scientists in BC to receive $2.7 million in funding Genome BC announces the second round of funding through the Science Opportunities Fund.
|
|
June 05 2009
Biodiesel gets a monetary boost thanks to feds The federal government has made an investment in the Western Biodiesel’s facility in High River, which will receive up to $19.9 million over seven years to support biofuels development.
|
|
May 29 2009
Protox announces private placement Protox Therapeutics Inc. intends to raise gross proceeds of up to CDN $1.5 million through a private placement of common shares of the company at a price of $0.27 per share.
|
|
May 29 2009
William MacKinnon elected to Novadaq board of directors Novadaq Technologies Inc. announces that William A. MacKinnon, FCA, retired chief executive officer of KPMG Canada, has been elected to the company's board of directors and will serve as the board's audit committee chair.
|
|
May 29 2009
Warnex enters into agreement in principle for the acquisition of Molecular World Inc. Warnex Inc. enters into an agreement in principle for the acquisition of Molecular World Inc., a laboratory located in Thunder Bay, ON, specialized in human DNA identification including forensic DNA testing.
|
|
May 29 2009
GenoLogics, JMP Genomics to provide end-to-end data management and analysis GenoLogics and SAS announce plans to integrate the Geneus lab and data management solution with the JMP Genomics statistical discovery application from SAS to provide a comprehensive system for managing and analyzing large genomic data sets.
|
|
May 22 2009
2009 BIO International Convention provides forum for networking, deal making and partnering The 2009 BIO International Convention, produced by the Biotechnology Industry Organization (BIO), wrapped up today at the Georgia World Congress Center with 14,352 industry leaders from 58 countries and 48 states.
|
|
May 22 2009
The 2009 Premier's Innovation Awards ceremony takes place in Toronto The Ontario Premier's Innovation Awards were recently held in Toronto where 12 awards were presented in three categories. More than $12 million was awarded to the winners and Premier Dalton McGuinty was on-hand to deliver the keynote address.
|
|
May 22 2009
Canada’s Technology Triangle Inc. and Perimeter Institute for Theoretical Physics win Global City Award Through the efforts of Canada’s Technology Triangle Inc and the Perimeter Institute for Theoretical Physics – the Waterloo Region is reshaping the Canadian “brain drain” and becoming an international “brain gain” region, earning the Canadian Urban Institute’s 2009 Global City Award to be granted June 5 at the Urban Leadership Awards in Toronto.
|
|
May 22 2009
U of S awarded $3.73M to lead health research training projects With $3.73 million from the Canadian Institutes of Health Research, University of Saskatchewan health scientists will train the next generation of health researchers through two unique-in-Canada projects-one in synchrotron imaging and the other in rural health and safety.
|
|
May 19 2009
Federal government invests in BC solar energy program The federal government invests $400,000 in the Solar Hot Water Heating program through the ecoENERGY for Renewable Heat initiative.
|
|
May 19 2009
ASKA Research and CNS become first companies to sign strategic partnership agreement ASKA Research and Clinical Network Services (CNS) announce the signing of a mutual Strategic Partnership Agreement (SPA) that will expand their global market share.
|
|
May 19 2009
Medicago receives 2009 Genesis Innovation award Medicago Inc. has received the 2009 Genesis "Innovation" award at a gala presented by BIOQuebec last week, in Montrea. The Genesis Awards recognizes outstanding achievements by companies that play a key role in the growth of Quebec's biotech, health technology and life sciences industries.
|
|
May 19 2009
Dealmakers Oncolytics Biotech (Calgary, AB) has completed its acquisition of an inactive private company.
MedMira Inc. (Halifax, NS) and Tri-Star Industries form a strategic marketing partnership. Orcrist Bio Inc. (Calgary, AB) announces the approval of its Phase I, open-label, single-ascending-dose. |
|
May 19 2009
Merck & Co., Inc. and Cardiome sign license agreement Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.
|
|
May 19 2009
Viterra launches Pulse Star™ herbicide Viterra Inc. announces the availability of Pulse Star™, a new addition to the company’s line-up of Viterra branded crop protection products.
|
|
May 19 2009
Pharma Notes BioMS Medical Corp.
Resverlogix Corp. Medifocus Inc. Orcrist Bio Inc. Oncolytics Biotech Inc. MedMira Inc. Cytochroma SemBioSys Genetics Inc. |
|
May 19 2009
Appointments MedMira Inc. appoints André Archimbaud to its board of directors.
WEX Pharmaceuticals Inc. appoints Dr. Larry Gontovnick to the position of vice president. Canadian Institutes of Health Research appoints Dr. Anthony Phillips as incoming scientific director of CIHR’s Institute of Neurosciences. GeneNews Ltd. announces the appointment of Dr. David Sable to its board of directors. |
|
May 15 2009
Ontario takes additional legal action in drug purchasing scheme Ontario is taking legal action against more pharmacies and wholesalers that have been involved in a scheme where drug products were being sold several times.
|
|
May 15 2009
Canadian government provides new funding for Red Deer ethanol plant Earl Dreeshen, Member of Parliament for Red Deer, on behalf of the Honourable Lisa Raitt, Minister of Natural Resources, announces that the Canadian government will provide up to $23.2 million through its ecoENERGY for Biofuels program to Permolex Ltd.
|
|
May 15 2009
Clinical Trials & Patents Allon Therapeutics (Vancouver, BC) announces that the intellectual property underlying its activity-dependent neurotrophic factor.
Medifocus Inc. (Vancouver, BC) releases positive clinical results. BioMS Medical Corp. (Edmonton, AB) announces that the independent Data Safety Monitoring Board (DSMB) for the company’s U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. Oncolytics Biotech Inc. (Calgary, AB) completes patient enrolment in its U.K. clinical trial |
|
May 15 2009
National Research Council putting its stamp on International Year of Astronomy The National Research Council Canada (NRC) and Canada Post unveils two new stamps that celebrate that celebrate the International Year of Astronomy while recognizing Canada’s Gold Medal contributions to exploring the stars.
|
|
May 15 2009
Simon Fraser University Chemistry wing to get $50 million facelift Simon Fraser University’s chemistry wing, built in 1965, will get a $49.4 million facelift over the next two years. The provincial government and Industry Canada’s Knowledge Infrastructure program will jointly fund the project.
|
|
May 15 2009
CFI investment advances U of S Health and space research University of Saskatchewan (U of S) researchers have been awarded a total of $445,907 from the Canada Foundation for Innovation (CFI) in support of research projects on space simulation, population health, mental disorders, and other areas.
|
|
May 15 2009
Protox appoints chief financial officer Protox Therapeutics Inc. appoints John Parkinson to the position of chief financial officer of the company, effective immediately. Parkinson replaces David Swetlow, vice president of Finance and Operations, who is leaving Protox to pursue entrepreneurial opportunities.
|
|
May 15 2009
Med BioGene Inc. appoints life science veteran David Matthews as CFO Med BioGene Inc. (MBI) appoints David Matthews as chief financial officer. Matthews brings over 20 years of experience in funding and operating life science companies and will play a critical role in executing LungExpress Dx™ commercialization strategy.
|
|
May 08 2009
Ontario government investing in science to strengthen economy Ontario announces that it is launching a fund to attract and retain world-leading genomics researchers in the province. The $100-million Global Leadership Round in Genomics and Life Sciences will support globally-significant, collaborative research projects that are headquartered in Ontario. This fund will create high-skilled jobs in research and technology, and brings Ontario’s commitment to funding science since 2003 to a historic high of $1.4 billion.
|
|
May 04 2009
LAB Research secures $7.5 million financing from Investissement Québec LAB Research Inc. secures a $7.5 million loan from Investissement Québec, a Quebec government agency, as part of its "Renfort" program.
|
|
May 04 2009
Urodynamix receives financial contribution from NRC-IRAP Urodynamix Technologies Ltd. receives approval for a non-refundable financial contribution of up to $322,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).
|
|
May 04 2009
Queen’s competes for new Research Chair in Nuclear Materials Queen's University has won a place in the first phase of a nationwide competition in a new federal research program.
|
|
May 04 2009
Federal government delivers nuclear research funding to Canadian universities After an investment by the Canadian government, 23 research projects at universities across the country will receive funding to develop advanced nuclear energy systems. These projects will encourage technology innovation, create jobs and boost Canada’s economy.
|
|
April 29 2009
Ontario clinics adapt new system – gain real-time access to records Ontario clinics have adapted a system that allows it to gain real-time access to the medical records of its patients, helping to improve delivery of care and formulate more detailed diagnosis.
|
|
April 29 2009
Mississauga Mayor Hazel McCallion honoured Mississauga Mayor Hazel McCallion has been honoured with the Community Service Award at the annual Biotechnology Initiative awards dinner last month.
|
|
April 29 2009
CV Technologies announces revenue is on the rise CV Techologies Inc., announces that revenue for the fiscal year ended September 30, 2008 rose 17.5% to $49.4-million from $42-million in the previous fiscal year.
|
|
April 29 2009
Allon Therapeutics confirms company has enough resources to fund into 2011 Allon Therapeutics, a clinical-stage biotechnology company specializing in developing treatments for major neurodegenerative conditions, confirms that the company’s existing cash resources will fund the business into 2011.
|
|
April 29 2009
Dealmakers LAB Research Inc. (Laval, QC) has settled outstanding litigations with Akela Pharma Inc.
Æterna Zentaris Inc. (Mississauga, ON) announces its signing of a development. Thermapure BioPharma Inc. (Toronto, ON) and LFB Biotechnologies announce a service contract for the development of a manufacturing method for an innovative plasma therapeutic protein. Vasogen Inc. (Mississauga, ON) has sold is United States patent application and its related foreign counterparts. AEterna Zentaris (Quebec, QC) has inked a $165 million licensing deal with Sanofi-aventis (Laval, QC) GenoLogics (Victoria, BC) announces that Wellcome Trust (London, UK) is deploying its lab and data management solution for genomics. |
|
April 29 2009
Pfizer Canada makes $1 million contribution Pfizer Canada will contribute $1-million to the Prevention of Organ Failure (PROOF) Centre of Excellence for Commercialization and Research, helping to fund research into biological molecules that indicate disease called biomarkers.
|
|
April 29 2009
BioSyntech Inc.'s founder resigns BioSyntech Inc., a biotechnology company specializing in biotherapeutic thermogels for regenerative medicine announces that its founder, Dr. Amie Selmani, has resigned from its board of directors effective immediately.
|
|
April 29 2009
GeneLogics secures financing GeneLogics secured $5-million in financing, which it will use towards ongoing expansion plans.
|
|
April 24 2009
BioAlberta announces Calgary’s regional winner of the Sanofi-Aventis BioTalent Challenge Research in biotechnology has paid off for five teams of high school students, who received cash prizes from the Calgary regional 2009 Sanofi-Aventis BioTalent Challenge.
|
|
April 24 2009
U of S researcher named Einstein Professor by Chinese Academy of Sciences University of Saskatchewan toxicologist John Giesy has been named an Einstein Professor by the Chinese Academy of Sciences (CAS), a distinction reserved for research leaders with the potential to win Nobel and other international science awards.
|
|
April 20 2009
Patheon Inc. expands Toronto facility Patheon Inc. announces the expansion of its Toronto manufacturing facility. The expansion adds 10,000 square feet of GMP space dedicated to the production of oral contraceptives with a potential output of 1.3 billion tablets.
|
|
April 16 2009
ImmunoVaccine Technologies collaborates with Defence Research & Development Canada ImmunoVaccine Technologies Inc. (IVT) announces the signing of a three year research agreement with Defence Research and Development Canada (DRDC).
|
|
April 14 2009
Axela introduces Amine Reactive Sensor Axela introduces the dotLAB Amine Reactive Sensor for direct covalent coupling of affinity reagents for use with the dotLAB System.
|
|
April 08 2009
The Ontario Cancer Biomarker Network selects GenoLogics Proteomics Lab and Data Management Solution GenoLogics announces it is working with the Ontario Cancer Biomarker Network to deploy its lab and proteomics data management system.
|
|
April 08 2009
Viterra recognized with two Paragon Awards Viterra Inc. is the recipient of the Paragon Business of the Year and Export Achievement awards sponsored by the Regina & District Chamber of Commerce.
|
|
April 06 2009
Viterra appoints two senior vice-presidents Viterra Inc. promotes two of its executives. Ray Dean has been appointed senior vice-president, General Counsel/Corporate Secretary and Colleen Vancha has been promoted to senior vice-president Investor Relations and Corporate Affairs.
|
|
April 06 2009
Patheon signs agreement with Swiftwater Group to expand regulatory consulting services Patheon Inc. announces a new partnership with Swiftwater Group, LLC. Patheon and Swiftwater Group will combine resources to provide regulatory consulting services to clients.
|
|
April 03 2009
COLD-FX® maker changes company name to Afexa Life Sciences Inc. CV Technologies has changed the company's name to Afexa Life Sciences Inc. as part of a broader rebranding plan.
|
|
April 03 2009
InSite Vision receives regulatory approval for AzaSite® in Canada InSite Vision Incorporated announces that the Therapeutic Products Directorate (TPD) of Health Canada has approved the company’s new drug submission (NDS) for AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis (pink eye) in adults and children one year and older.
|
|
April 03 2009
Mississauga, ON, chosen by global pharmaceutical company for Canadian head office Mississauga, ON, was selected by Takeda Pharmaceutical Company Limited, a leading Japanese life sciences company, as the location for its new Canadian head office.
|
|
April 03 2009
National Research Council putting its stamp on International Year of Astronomy The National Research Council Canada (NRC) and Canada Post unveil two new stamps that celebrate the International Year of Astronomy while recognizing Canada's Gold Medal contributions to exploring the stars.
|
|
March 27 2009
Science undergrad Canada’s top co-op student A Simon Fraser University student whose accomplishments are catching the attention of international scientists is the third SFU student in the last seven years to be named one of Canada’s top co-op students.
|
|
March 20 2009
Canadian government invests in fibre research to help farmers The Canadian government is investing in the hemp and flax industry so that farmers can harness new opportunities and access new value added markets. The Honourable Vic Toews, Member of Parliament for Provencher and President of the Treasury Board, announces a $9.6 million investment in the Natural Fibres for the Green Economy Network (NAFGEN).
|
|
March 20 2009
The Institute for Bioanalytics, L.L.C. (IBA) expands assay development services Don Very, Ph.D., vice president, Research of IBA announces that IBA’s Assay Development Laboratory is now offering customers enhanced assay development services with the recent acquisition of a dotLab® System – an enabling platform for the development and deployment of assays.
|
|
March 19 2009
Canadian government invests in new crop varieties The Canadian government is creating new economic opportunities for farmers by investing in research that will expand market possibilities.
|
|
March 19 2009
Æterna Zentaris and Sanofi-Aventis sign a development, commercialization and licensing agreement Æterna Zentaris Inc. signs a development, commercialization and licensing agreement with sanofi-aventis for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market.
|
|
March 16 2009
LAB Research Inc announces board changes LAB Research Inc. announces the nomination of Carl A. Spalding as chairman of its Board of Directors in replacement of Karsten Skydsgaard who previously communicated a wish to step down from the Board to focus on his other professional obligations.
|
|
March 16 2009
Stem Cell Therapeutics Corp. announces appointment of new chief financial officer Stem Cell Therapeutics Corp. announces that Barry Herring has been appointed as the new vice president of Finance and chief financial officer (CFO), effective immediately.
|
|
March 16 2009
Dealmakers BioSyntech (Laval, QC), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, announces its financial and operational results for the third quarter of fiscal 2009.
YM BioSciences Inc. (Mississauga, ON) reports operational and financial results for the second quarter of fiscal 2009. Axela Inc. (Toronto, ON) announces that it is delivering on its strategic decision to expand into the rapidly growing North American agricultural biotechnology market. |
|
March 16 2009
Amorfix awarded "Life Science Company of the Year" Amorfix Life Sciences Ltd. has been selected as the inaugural recipient of the "Life Science Company of the Year" by The Biotechnology Initiative.
|
|
March 06 2009
Canadian government announces funding for leading biotechnology firm’s project Performance Plants Inc. announces that a project led by PPI will be receiving up to $5,565,063 in funding from SDTC. The funds will be used to advance its trait technologies that improve conversion of cellulose into cost-effective biofuels and biochemicals.
|
|
March 06 2009
Canada's Technology Triangle Inc. launches new website The team at Canada’s Technology Triangle Inc. announces the launch of its new website at www.techtriangle.com. The CTT website has been completely redesigned and rebuilt, and offers improved search and browsing features, as well as additional resources to best serve our clients’ needs.
|
|
March 06 2009
Mayor McCallion receives biotechnology award The Biotechnology Initiative (TBI) has honoured Mayor Hazel McCallion with the Community Service Award at its annual awards dinner in Toronto.
|
|
March 06 2009
Vineland enables industries’ efforts to build agri-science research cluster Vineland Research and Innovation Centre will attempt to answer the question of how a science cluster works with its model for the future.
|
|
March 06 2009
Canada's Technology Triangle Inc. launches new website The team at Canada’s Technology Triangle Inc. announces the launch of its new website at www.techtriangle.com . The CTT website has been completely redesigned and rebuilt, and offers improved search and browsing features, as well as additional resources to best serve our clients’ needs.
|
|
February 23 2009
Amorfix extends warrant term by one year Amorfix Life Sciences Ltd. extendd by one year the term of 4,462,521 common share purchase warrants (the "Warrants"), which are exercisable for one common share of Amorfix at an exercise price of $1.95 and were issued on March 8, 2007 as part of a private placement.
|
|
February 23 2009
BioSyntech appoints chief financial officer BioSyntech, Inc. appoints Louis Lemire, CA, to the position of chief financial officer. Lemire joined the company as a consultant in October 2008 and was appointed vice president, Finance in December 2008.
|
|
February 20 2009
Therapure Biopharma and LFB Biotechnologies announces contract A development services contract has been made between Therapure Biopharma Inc. and LFB Biotechnologies, a subsidiary of LFB SA, for the development of a manufacturing method for an innovative plasma therapeutic protein.
|
|
February 20 2009
PROOF Centre for Excellence partners with Pfizer Canada Pfizer Canada and the PROOF (PRevention Of Organ Failure) Centre of Excellence for Commercialization and Research announce they are teaming up in the fight against vital organ failure (heart, lung and kidney).
|
|
February 20 2009
OGI launches programs to increase Ontario genomics research capacity The Ontario Genomics Institute (OGI) launches two programs designed to increase Ontario’s competiveness in genomics research and innovation.
|
|
February 18 2009
Biotech Inc. announces appointment of new CFO Biotech Inc. announces the appointment of Yue Zhao as chief financial officer (CFO) of the company, effective immediately. Zhao brings in more than 16 years’ financial and accounting experience from private and public companies.
|
|
February 18 2009
Medicago appoints new member to board of directors Medicago Inc. announces that Pierre Des Marais II, longstanding board member of numerous companies, has been appointed to its board of directors.
|
|
February 18 2009
Agrium provides update Agrium Inc. announces that it expects to record a write-down in Retail in the fourth quarter of 2008 of approximately $96-million ($0.41 diluted earnings per share), of which $11-million is for the South American Retail operation and $85-million is for the North American Retail operations.
|
|
February 18 2009
SemBioSys announces senior management changes The board of directors of SemBioSys Genetics Inc. announces that current president and CEO Andrew Baum has been appointed to the new position of president and CEO of Botaneco Specialty Ingredients Inc., a SemBioSys subsidiary. James Szarko, currently the corporation’s chief financial officer, has been named the new president and chief executive officer of SemBioSys, effective immediately.
|
|
February 18 2009
Dealmakers CV Technologies (Vancouver, BC) has been selected as the official cold and flu remedy of the Vancouver 2010 Olympic and Paralympic Winter Games (VANOC).
Novadaq Technologies Inc. (Toronto, ON) enters into a multi-year technology alliance with Intuitive Surgical Inc. Urodynamix Technologies Ltd. (Vancouver, BC) obtains 510(k) clearance from the U.S. Food and Drug Administration. Paladin Labs Inc. (Montreal, QC) enters into a licensing and distribution agreement. |
|
February 18 2009
QSV Biologics Ltd. announces the appointment of Dr. William Cochrane O.C., M.D. QSV Biologics Ltd appoints Dr. William Cochrane O.C., M.D., as chairman of its board of directors.
|
|
February 18 2009
Novadaq completes staff reductions and announces management changes Novadaq® Technologies Inc. announces a strategic restructuring including senior management changes and the completion of a staff reduction of 25 employees that was initiated during Q3-2008. Following the restructuring, Novadaq will have approximately 60 employees.
|
|
February 13 2009
The Association of Canadian Academic Healthcare Organizations (ACAHO) reacts to the 2009 federal budget The Association of Canadian Academic Healthcare Organizations (ACAHO), congratulates the federal government on its series of infrastructure investments through Canada Health Infoway ($500 million) and the Canada Foundation for Innovation (CFI - $750 million).
|
|
February 13 2009
Research Canada reacts to the 2009 Federal Budget Research Canada: An Alliance for Health Discovery is pleased with a number of measures in the Federal Government’s 2009 Budget, including the more than $1.5 Billion investment in science and technology.
|
|
February 13 2009
Genome Canada reacts strongly to the 2009 Federal Budget Genome Canada is pleased with the federal government’s 2009 budget in which millions will be invested in research infrastructure over the next two years.
|
|
February 13 2009
The Association of Faculties of Medicine of Canada (AFMC) responds to the 2009 Federal Budget The Association of Faculties of Medicine of Canada (AFMC) is pleased with several measures contained in the 2009 Federal Budget.
|
|
February 13 2009
Memorial University is both optimistic and concerned about the 2009 Federal Budget Dr. Eddy Campbell is cautiously optimistic about the new federal budget, but Memorial's acting president warns that the impact of the budget on federal transfers to Newfoundland and Labrador may present other challenges to the university.
|
|
February 13 2009
The Association of Universities and Colleges of Canada welcomes the 2009 Federal Budget The Association of Universities and Colleges of Canada welcomes the new investment in Canada’s university infrastructure and the Canada Foundation for Innovation funding announced in today’s federal budget.
|
|
February 06 2009
Oncolytics Biotech Inc. announces start of patient enrolment in translational clinical trial investigation Oncolytics Biotech Inc. announces that patient enrolment has begun in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN® in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator is Professor Alan Melcher of St. James’s University Hospital.
|
|
February 06 2009
Urodynamix Technologies Ltd. receives FDA 510(k) clearance Urodynamix Technologies Ltd. announces that it has obtained 510(k) clearance from the U.S. Food and Drug Administration to market the UroNIRS 2000™ Bladder Monitor System – a second generation non-invasive medical device that uses near infrared spectroscopy (NIRS) to aid in the diagnosis of lower urinary tract symptoms (LUTS) in a urology office setting.
|
|
February 05 2009
Patheon announces closing of Carolina facility Patheon announces that after pursuing all reasonable alternatives for the past 12 months, it has elected to close its Carolina facility in Puerto Rico effective January 31, 2009.
|
|
February 05 2009
$206 million for economic development in Southern Ontario good news for Canada’s Technology Triangle Canada’s finance minister envisions a $34 billion deficit this year, followed by forecasted deficits until 2013, with the plan of spending $40 billion over the next two years to stimulate Canada's economy. The hope is that Canada will bounce back by 2010.
|
|
January 26 2009
Novadaq signs license, development and supply agreements Novadaq(R) Technologies Inc. enters into a multi-year technology alliance with Intuitive Surgical Inc. Novadaq is a developer of real-time medical imaging systems and image guided therapies for the operating room.
|
|
January 22 2009
COLD-FX chosen as official cold/flu remedy of the 2010 Olympics Dave Cobb, Vancouver Organizing Committee for the 2010 Olympic and Paralympic Winter Games (VANOC) executive vice-president, revenue, marketing and communications, and Dr. Jacqueline Shan, president and chief scientific officer of CV Technologies Inc., the maker of COLD-FX, joined Olympian Clara Hughes today at the Richmond Olympic Oval to announce COLD-FX as Official Supplier in the category of cold and flu remedies for the 2010 Winter Games.
|
|
January 22 2009
Government invests in sustainable infrastructure research Universities, municipal governments, and companies in Saskatchewan will be able to work together to develop innovative solutions to assess, maintain, develop, and renew vital public infrastructure and municipal services such as drinking water, stormwater, and wastewater systems.
|
|
January 22 2009
Funding for Arthritis sends positive message The Canadian Arthritis Network (CAN), a member of the Networks of Centres of Excellence (NCE), will continue to receive nearly $4.1 million per year ($12.2 million total), until March 2012, when its 14-year-term ends.
|
|
January 21 2009
Therapure Biopharma Inc. announces manufacturing agreement Therapure Biopharma Inc. signs a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.
|
|
January 21 2009
Chemtrade Logistics Income Fund more than doubles third quarter net earnings Chemtrade Logistics Income Fund announces results for the three months ended Sept. 30, 2008.
|
|
January 21 2009
Dealmakers YM BioSciences Inc. (Mississauga, ON) announces that its majority-owned subsidiary CIMYM BioSciences Inc. has received a milestone payment from its licensee.
Terasen Energy Services (Burnaby, BC) signs an agreement with The Beedie Group. The Standards Council of Canada (Ottawa, ON), a Crown corporation with the mandate to promote efficient and effective standardization in Canada. GeneNews Limited (Toronto, ON) announces the formation of a Canadian Colorectal Cancer Advisory Board. |
|
January 21 2009
ProMetic signs $35 million long-term supply agreement ProMetic Life Sciences Inc. announces that its U.K.-based subsidiary, ProMetic BioSciences Ltd (“PBL”), has signed a long-term supply agreement.
|
|
January 21 2009
Theratechnologies announces expiry of the waiting period Theratechnologies announces that the Hart-Scott Rodino Act waiting period has expired with respect to the collaboration and licensing agreement with EMD Serono, Inc.
|
|
January 15 2009
Vineland builds on innovation and research through collaboration Vineland Research and Innovation Centre announces it has executed Memorandums of Understanding each with both Brock University and Niagara College with the objective for these organizations to work collaboratively on horticulture and agriculture research.
|
|
January 15 2009
NRC joins global science gateway The NRC has joined an international alliance established to oversee access to global research information. The initiative works through the WorldWideScience.org website.
|
|
January 15 2009
Canada Foundation for Innovation invests in research infrastructure The Canada Foundation for Innovation (CFI) announces a $45 million investment under its Leaders Opportunity Fund (LOF).
|
|
January 14 2009
YORKbiotech appoints chief administrative officer The Executive Committee of YORKbiotech appoints Mary Anne Viani as chief administrative officer. She comes highly recommended as a person to assist the board in enlarging the mandate of YORKbiotech and the National Centre for Medical Device Development. She will also handle overall administrative duties for YORKbiotech and continue to provide services to members.
|
|
January 14 2009
UNB professor receives National award created in his honour UNB professor Paul Williams, an outstanding scholar who nurtured the careers of dozens of graduate students, has been honored by the Canadian Federation of Earth Sciences (CFES), which has created a national award in his honour.
|
|
January 14 2009
Economic development agencies promote co-operation and collaboration Economic development executives from across the country have met in Ottawa in order to work together with federal government departments and agencies on a unified business attraction strategy that recognizes the dominant role of urban economies. According to members of the Canada International Work Group, Canada's largest cities represent more than 50% of Canada's economic activity.
|
|
January 12 2009
CV Technologies announces strong return to profitability and double digit revenue growth CV Technologies Inc. announces that revenue for the fiscal year ended Sept. 30, 2008 rose 17.5% to $49.4 million from $42.0 million in fiscal 2007. Net earnings increased to $4.6 million ($0.04 per common share) in fiscal 2008, a $14.4 million improvement from the fiscal 2007 net loss of $9.8 million ($0.09 loss per common share).
|
|
January 12 2009
Theratechnologies announces senior management change Theratechnologies announces the departure of Dr. Pierre Caudrelier, as chief medical officer, effective immediately, to pursue other career opportunities.
|
|
January 09 2009
Vasogen provides corporate update Pursuant to a previously announced restructuring plan, Vasogen has been reviewing strategic alternatives for the purpose of enhancing shareholder value.
|
|
January 09 2009
PEI Bio Alliance welcomes new innovation programs The PEI BioAlliance welcomes the recent announcement by the government of Prince Edward Island that it is preparing to launch a series of new initiatives to advance innovation and business growth within priority sectors in the Province, including Biosciences.
|
|
January 09 2009
Ondine Biopharma announces management and board changes Ondine Biopharma Corporation announces a reorganization to its senior management team reflecting the company's focus on the development of its photodisinfection product pipeline. Dr. Cale Street has been appointed vice-president of Research of Ondine's wholly-owned subsidiary, Ondine Research Laboratories, Inc.; located at the company's research facilities in Bothell, Washington.
|
|
December 22 2008
BioSyntech announces management changes BioSyntech, Inc. announces that Francois Michaud has tendered his resignation as CFO, effective February 16, 2009.
|
|
December 16 2008
Eugene Melnyk makes purchase of Biovail shares Eugene Melnyk, currently the biggest shareholder of Canadian drugmaker Biovail Corp., has increased his position in the company by buying approximately 4.7 million shares, or 2.9%, of the outstanding shares, at C$10.86 each for a total value of C$50.7 million. This purchase boosts his position to 13.5%.
|
|
December 16 2008
Microbix uses core business cashflow to fund late-stage pipeline Microbix announces results for the fiscal year ended Sept. 30, 2008. Revenues from its profitable core business are continuing to fund Microbix Biosystems Inc.’s late-stage pipeline opportunities, which are expected to build shareholder value in the short and long term, according to William J. Gastle, CEO of the company.
|
|
December 16 2008
Chemtrade Logistics Income Fund more than doubles third quarter net earnings and distributable cash Chemtrade Logistics Income Fund announces the results for the three months ended Sept. 30, 2008. Continuing high prices for sulphuric acid resulted in significant increases in revenue and earnings for Chemtrade's Sulphur Products & Performance Chemicals and International segments, which were the primary contributors to the third quarter's higher results.
|
|
December 16 2008
CardioComm Solutions Inc. announces changes to board of directors CardioComm Solutions, Inc. announces that Michael Paquin and Yury Levin have been appointed to the board of directors, effective immediately. Michael Paquin is well recognized as a leading healthcare strategist. His insight and innovation to device connectivity into the EMR have been acknowledged by Microsoft, Frost & Sullivan, TEPR and TETHIC.
|
|
December 12 2008
Stellar Pharmaceuticals Inc. signs licensing agreement Stellar Pharmaceuticals Inc. signs a licensing agreement for the distribution and sale of Uracyst(R) in Denmark, Finland, Iceland, Norway and Sweden, with Vitaflo Scandinavia AB ("Vitaflo"), a specialty pharmaceutical sales and marketing company, which is a subsidiary of Navamedic ASA.
|
|
December 11 2008
Young scientists rewarded for their research During the 5th International Symposium on Probiotics 'Cross Talk Now!', organized by INITIA in Quebec City last month, the winners of the Rosell Probiotic Challenge were announced.
|
|
December 11 2008
Patheon re-launches its alliance with Depomed™ Patheon Inc. re-launches its alliance with Depomed™, a specialty pharmaceutical company focused on enhancing pharmaceutical products, as part of Patheon’s commitment on providing the best development and commercialization service offerings.
|
|
December 11 2008
Amorfix receives third Biogen Idec investment Amorfix Life Sciences announces that Biogen Idec made its third investment in Amorfix with the purchase of 608,250 shares for gross proceeds to Amorfix of US$150,000.
|
|
December 11 2008
Urodynamix and Pfizer Inc. launch promotional program in Boston Urodynamix Technologies Ltd. and Pfizer Inc. begin a series of promotional programs to increase awareness of uroNIRST Bladder Monitor technology among urologists, medical professionals, and key opinion leaders.
|
|
December 11 2008
Æterna Zentaris agrees to sell Cetrotide® royalty stream Æterna Zentaris Inc. signs a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P. (“CHRP”) its rights to royalties on future sales of Cetrotide® covered by its license agreement with Merck Serono.
|
|
December 11 2008
Dealmakers Patheon (Toronto, ON) Patheon and Senopsys LLC have formed an alliance to develop dose formulations which enhance palatability (taste) for drugs that are in development.
|
|
December 11 2008
Illumina selects GenoLogics as next generation sequencing partner GenoLogics announces that Geneus, its lab and data management system for genomics, was selected by Illumina to provide a combined solution offering with the Illumina sequencing platform, Genome Analyzer.
|
|
December 08 2008
Ambrilia Biopharma and ZBx Corporation enter into an exclusive license option agreement Ambrilia Biopharma Inc. enters into an exclusive license option agreement with ZBx Corporation granting ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia's PSP94 technology in ZBx's Zap(TM) Rapid Test Systems and Assays.
|
|
December 08 2008
Paladin Labs and GlaxoSmithKline Inc. sign agreement Paladin Labs Inc. signs an agreement with GlaxoSmithKline Inc. (GSK) and Glaxo Group Limited that appoints Paladin Labs Inc. as the exclusive distributor of Dexedrine(R) (dextroamphetamine sulfate) within Canada for a period of three years, with an option for Paladin to purchase all remaining rights to the product in Canada at the end of that period.
|
|
December 08 2008
Æterna Zentaris closes sale of Cetrotide® royalty stream for $52.5 million Æterna Zentaris Inc. completes the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, L.P. (“CHRP”) relating to Æterna Zentaris’ rights to royalties on future sales of Cetrotide® covered by its license agreement with Merck Serono. Æterna Zentaris received $52.5 million from CHRP at closing, less certain transaction costs.
|
|
December 04 2008
New neurological network aims to be world leader Queen's neuroscientists are joining forces with colleagues at York and Western universities to better understand how the brain works, especially in human movement control and perception, and how disease and injury can disrupt these functions.
|
|
November 28 2008
53 high-skill jobs coming to Pickering, ON Purdue Pharma Canada will be hiring 53 people to work in research, development and advanced manufacturing with the expansion of its operations in Pickering, ON.
|
|
November 24 2008
LAB Research launches business development platform LAB Research Inc. announces the implementation of a new business development platform in Europe to leverage the recent Good Laboratory Practices recertification of both the Hungarian and Danish sites, as well as the recent expansion of these two European laboratories.
|
|
November 24 2008
ViRexx announces appointment of directors ViRexx Medical Corp. appoints two new directors to its board and on Oct. 16, 2008 the company filed a Notice of Intention ("NOI") to make a proposal to its creditors pursuant to the Bankruptcy and Insolvency Act (Canada) ("BIA").
|
|
November 24 2008
Patheon and Solvias AG announce global strategic alliance Patheon and Solvias AG announce a global alliance to offer integrated development services to pharmaceutical and biotechnology companies. This alliance combines Patheon's experience and expertise in formulation development with Solvias AG's reputation in pre-formulation and solid state chemistry.
|
|
November 24 2008
Ambrilia initiates plan aiming to reduce operations in France Ambrilia announces that it intends to initiate a plan aiming to significantly reduce its activities in France.
|
|
November 21 2008
Ambrilia initiates plan aiming to reduce operations in France Ambrilia announces that it intends to initiate a plan aiming to significantly reduce its activities in France.
|
|
November 21 2008
Patheon and Omnicare sign agreement Patheon signs a master service agreement with Omnicare Clinical Research, a leading global CRO, for distribution of clinical trial materials in Europe and Asia Pacific.
|
|
November 21 2008
Urodynamix appoints chief financial officer Urodynamix Technologies Ltd. appoints Jonathan Jackson, CA as chief financial officer.
|
|
November 17 2008
Urodynamix Technologies Ltd. enters into a product development and distribution agreement Urodynamix Technologies Ltd. (Vancouver, BC) enters into a product development and distribution agreement with Timm Medical Technologies Inc. (Eden Prairie, MN), a subsidiary of Plethora Solutions Holdings PLC.
|
|
November 17 2008
Urodynamix Technologies Ltd. enters into a worldwide distribution agreement Urodynamix Technologies Ltd. (Vancouver, BC) enters into a worldwide distribution agreement with Medical Measurement Systems B.V.
|
|
November 17 2008
Calyx Bio-Ventures Inc. has completed a plan of arrangement involving, Chromos Molecular Systems Inc. and Modatech Systems Inc. Calyx Bio-Ventures Inc. (Vancouver, BC) has completed a plan of arrangement involving, Chromos Molecular Systems Inc. (Vancouver, BC) and Modatech Systems Inc. pursuant to the arrangement and related transactions.
|
|
November 17 2008
Acasti Pharma Inc. a pharmaceutical subsidiary of Neptune Technologies & Bioressources Inc. announces it has acquired a majority of the non-convertible notes Acasti Pharma Inc. (Laval, QC), a pharmaceutical subsidiary of Neptune Technologies & Bioressources Inc. (Laval, QC) announces it has acquired a majority of the 9,380,355 non-convertible notes issued by Neptune.
|
|
November 17 2008
MethylGene Inc. announces that Celgene has terminated its licensing agreement for oncology histone deacetylase MethylGene Inc. (Montreal, QC) announces that Celgene has terminated its licensing agreement for oncology histone deacetylase (HDAC) inhibitors.
|
|
November 17 2008
Urodynamix and Laborie Medical expand distribution rights Urodynamix Technologies Ltd., announces that it has amended its distribution agreement with Laborie Medical Technologies Inc., to include worldwide non-exclusive sales, marketing and distribution rights for the TetraT Bladder Monitor System in the physician office and outpatient clinic markets in addition to the rights for the acute care setting previously granted.
|
|
November 14 2008
Viterra names new senior vice president Viterra Inc. appoints W.D. (Bill) Mooney to senior vice president, Livestock and Feed Services.
|
|
November 12 2008
Patheon expands PDS capacity in Canada Patheon Inc. opens a new Pharmaceutical Development Services (PDS) suite at the Whitby Development Centre in Canada.
|
|
November 12 2008
BioSyntech appoints new board members BioSyntech, Inc. announces that Michel Lagueux, Dr. Karen Hong, Eric W. Linsley and Winston Black have been appointed to its board of directors, effective immediately.
|
|
November 12 2008
Biovail appoints new VP neurologic and psychiatric development Biovail Corporation, a company focused on the development and commercialization of medicines that address unment medical needs in niche specialty central nervous system (CNS) markets, has appointed Dr. Neil M. Sussman as vice-president, neurologic and psychiatric development effective immediately.
|
|
November 12 2008
Neurologix licenses exclusive rights to key gene Neurologix, Inc. and Aegera Therapeutics have signed an exclusive license agreement.
|
|
November 12 2008
Chemokine Therapeutics engages investment banker Chemokine Therapeutics Corp. announces the engagement of Boenning & Scattergood Inc. as its exclusive advisor to assist the company in the implementation of previously announced strategic financial initiatives.
|
|
November 12 2008
Monsanto Canada makes internal appointments Monsanto Canada, a provider of technology-based solutions and agricultural products, announces two appointments in its canola and crop protection marketing group.
|
|
November 10 2008
Patheon establishes European headquarters in Switzerland Patheon opens its new headquarters for its European operations in Zug, Switzerland, near Zurich.
|
|
November 10 2008
GeneLogics signs global agreement with Pfizer GenoLogics signs a three year global agreement with Pfizer to provide informatics solutions to its research labs.
|
|
November 10 2008
Biovail appoints Dr. H. Christian Fibiger senior vice-president, chief scientific officer Biovail Corporation appoints Dr. H. Christian Fibiger as senior vice-president, chief scientific officer of Biovail Laboratories International SRL (BLS), the company's principal operating subsidiary.
|
|
November 07 2008
BC Advantage Funds announces Advantage Growth Fund BC Advantage Funds will change the name and investment focus of its Advantage Life Sciences Fund II to focus on investments in emerging BC-based growth companies. The name of the fund will change to the Advantage Growth Fund. Earlier stage, life science investments will continue to be made in the Advantage Venture Fund.
|
|
October 27 2008
Canadian Diabetes Association, the Canadian Society of Endocrinology and Metabolism, mdBriefCase and AdvancingIn team up The Canadian Diabetes Association, The Society of Endocrinology and Metabolism (CSEM), AdvancingIn and mdBriefCase Inc. announce a new partnership to provide on-line support for the Canadian Diabetes Association's 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada for healthcare professionals.
|
|
October 24 2008
Stellar Pharmaceuticals Inc. signs licensing agreement Stellar Pharmaceuticals Inc. signs a licensing agreement for the distribution and sale of Uracyst(R) in Turkey and the Turkish Republic of Northern Cyprus, with EIP, Eczacibasi Ilac Pazarlama A.S., which is based in Istanbul, Turkey.
|
|
October 24 2008
Lorus Therapeutics announces receipt of milestone payment Lorus Therapeutics Inc. receives a milestone payment of US$150,000 from Zor Pharmaceuticals LLC, a subsidiary of Zoticon Bioventures Inc., as it has achieved the milestone of raising the first tranche in financing for the development of Virulizin(R). This will bring the total payment to Lorus to $250,000.
|
|
October 17 2008
CV Technologies announces resignation of board chairman CV Technologies receives the resignation of Gordon Tallman, currently chairman of the board of directors, effective October 31, 2008. Following Tallman's departure, the board will be led on an interim basis by Kit Chan, vice chairman and Lead Independent director of the board.
|
|
October 17 2008
BC Advantage Funds increases stake in Urodynamix Technologies Ltd. Urodynamix Technologies Ltd. enters into an agreement with BC Advantage Funds wherein BC Advantage Funds has agreed, subject to normal closing conditions, to purchase 25,000,000 shares of the company at a price of $0.10 per share for total proceeds of $2.5 million.
|
|
October 17 2008
Vineland welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology Vineland Research and Innovation Centre appoints of Dr. Daryl Somers to the new role of Research Chair, Molecular Breeding and Biotechnology for the Centre.
|
|
October 16 2008
2008 OGI Genomics Teaching Prize awarded to Robert Malyk The Ontario Genomics Institute (OGI) announces Robert Malyk, senior biologist at Ridley College in St. Catharines, ON is the winner of the 2008 OGI Genomics Teaching Prize.
|
|
October 16 2008
Finalists announced in BioVenture Challenge Eight budding entrepreneurs—all University of Saskatchewan students or graduates 35 or under—have been named finalists in the 2008 BioVenture Business Plan Challenge and will go on to compete for a $50,000 prize to help take the winning business plan from idea to reality.
|
|
October 16 2008
Miraculins announces deal with Mount Sinai Services Miraculins Inc.signs a letter of intent with Mount Sinai Services (“MSS”), which will allow MSS to acquire FDA regulated commercial products known as Analyte Specific Reagents (“ASRs”) in order to develop in house clinical tests for Miraculins’ growing pipeline of biomarkers.
|
|
October 16 2008
Dealmakers Warnex Inc. (Laval, QC) announces that its Medical Laboratories division has obtained ISO accreditation by the Standards Council of Canada (SCC)
Biovail Corporation (Toronto, ON) acquires Prestwick Pharmaceuticals, Inc. OncoGenex Technologies Inc. (Vancouver, BC) reaches an agreement with the U.S. Food and Drug Administration (FDA) |
|
October 16 2008
CV Technologies announces CEO and board change CV Technologies announces that Dr. Jacqueline Shan, currently its president, chief executive officer and chief scientific officer, has decided to relinquish the position of chief executive officer in order to focus mainly on her role as chief scientific officer.
|
|
October 16 2008
Urodynamix Technologies Ltd. announces worldwide distribution partner to begin marketing in Europe Urodynamix Technologies Ltd. announces that its worldwide distribution partner, Laborie Medical Technologies Inc. has received CE Mark approval to begin marketing the Tetra Bladder Monitor System in Europe.
|
|
October 16 2008
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company BioMS Medical Corp. receives the US$10 million milestone payment from its partner, Eli Lilly and Company.
|
|
October 15 2008
Cigarette company partners with Medicago Global cigarette maker Philip Morris International is set to invest $16 million in Canadian vaccine developer Medicago Inc., taking a 49.9% stake which could grow to a majority holding.
|
|
October 15 2008
Government of Canada invests in British Columbia renewable energy project The Government of Canada is investing in a renewable energy project in British Columbia thanks to investments in projects through the ecoENERGY for Renewable Power Program.
|
|
October 10 2008
Warnex becomes exclusive Canadian distributor for GENDIA diagnostic tests Warnex Inc. announces that it has become the exclusive Canadian distributor of molecular diagnostic tests for GENDIA, an international network consisting of more than 50 laboratories located in the USA, Europe and Australia, offering more than 2,000 different genetic tests.
|
|
October 10 2008
Luminex receives clearance from Health Canada for xTag™ respiratory viral panel Luminex Corporation receives clearance from Health Canada for its xTAG™ Respiratory Viral Panel (RVP). xTAG RVP is a unique, groundbreaking test that, from one patient sample, simultaneously detects the 18 respiratory viruses and subtypes that are responsible for the majority of respiratory viral infections.
|
|
October 09 2008
Caprion awarded US$12.9M infectious disease biomarker research contract Caprion Proteomics Inc. has been awarded a $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out Biodefense research in the area of infectious disease biomarkers.
|
|
October 09 2008
Protox appoints Dr. Jack Geltosky to its board of directors Protox Therapeutics Inc. appoints Dr. Jack Geltosky to its board of directors. Dr. Geltosky is the senior vice president of Business Development at the Arizona Technology Enterprise where he is responsible for developing business strategies, licensing and partnering in the life sciences sector.
|
|
October 06 2008
Monsanto Canada awarded ‘Top 100 Canadian Employers’ by Maclean’s For the second consecutive year, Monsanto Canada has been selected as one of Canada's ‘Top 100 Employers’ by Maclean's magazine in its annual survey of Canadian businesses. The Maclean's listing appears in a special edition of the magazine.
|
|
October 06 2008
Patheon recognized for Most Effective Scale-Up and Technical Transfer Patheon wins the European Outsourcing Award (EOA) in conjunction with Procter and
Gamble Pharmaceuticals at this year’s event. Patheon won in the category of the Most Effective Scale-Up and Technical Transfer award. |
|
September 29 2008
LifeSciences British Columbia adds three industry leaders its board LifeSciences BC appoints three new board members representing leading life sciences companies in British Columbia. Ian Thompson, president, Canadian BioEnergy was appointed as of the September 16th board of directors’ meeting, and Dr. Stephen Gillis, managing director, ARCH Venture Partners; and Gordon MacCauley, president & chief executive officer, Allon Therapeutics were elected to LifeSciences BC’s Board of Directors. Dr. Robert Sindelar of UBC was also re-elected to the board of directors.
|
|
September 29 2008
Med BioGene completes final trance of financing Med BioGene Inc. has completed the second and final tranche of its previously announced public offering by way of short form prospectus through the issuance of 1,469,000 units at a price of $0.15 per unit for gross proceeds of approximately $220,000.
|
|
September 29 2008
CV Technologies announces board of director resignation CV Technologies Inc. announces that Patricia Trottier, a member of the board of directors of CV Technologies since 2004, and a member of the board's compensation committee and chair of the governance committee has decided to resign from the board for personal reasons.
|
|
September 25 2008
Patheon completes preferred share agreement amendment Patheon announces the completion of the agreement with JLL Patheon Holdings, LLC ("JLL") that was previously announced Sept. 5, 2008 and under which JLL has waived its right to the mandatory redemption provision of the Company's convertible preferred shares.
|
|
September 25 2008
Cytochroma appoints Steven I. Engel as vice president of Regulatory Affairs and Quality Assurance Cytochroma appoints Steven I. Engel, M.S., Pharm.D., as vice president, Regulatory Affairs and Quality Assurance. Dr. Engel brings to Cytochroma over 20 years of experience in regulatory affairs and quality assurance, and will be responsible for directing all of Cytochroma’s regulatory activities, as well as ensuring that the company has appropriate quality systems in place.
|
|
September 23 2008
Roche starts acquisition process of Arius to gain access to new screening platform Roche and ARIUS Research Inc. sign a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.
|
|
September 23 2008
Dealmakers Lorus Therapeutics Inc. (Toronto, ON) completes its rights offering to eligible shareholders raising total gross proceeds of $3.71 million.
Novatek International (Montreal, QC) and Labtronics (Guelph, ON) announce a partnership that leverages its complimentary technologies. Migenix Inc. (Vancouver, BC) announces it has reached an agreement with DJohnson Holdings Inc. Canada-based yeast company Lallemand Inc. (Montreal, QC) has acquired SA Bioproducts (Durban, SAF). Kane Biotech Inc. (Winnipeg, MB), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, enters into a material transfer and evaluation agreement. |
|
September 23 2008
SK Life Science, Inc. selects Patheon as development services partner Patheon has been selected by SK Life Science, Inc. (formerly known as SK Bio-Pharmaceuticals), the US-based subsidiary of Korean SK Holdings as its development services partner for two additional innovative Central Nervous System (CNS) drug candidates.
|
|
September 19 2008
Alberta Medical Association appoints new president, welcomes Canadian Medical Association president – elect to Edmonton The Alberta Medical Association (AMA) inducts its new president for 2008-09 during the annual general meeting (AGM) and Representative Forum (RF).
|
|
September 19 2008
Arius sale approved by shareholders Arius Research Inc. announces that ARIUS Research Inc. shareholders and warrant holders approved the proposed plan of arrangement involving the company and Roche.
|
|
September 18 2008
Med BioGene completes first tranche Med BioGene Inc. completes the first tranche of its previously announced public offering (the “Offering”) by way of short form prospectus through the issuance of 10,699,667 units (the “Units”) at a price of $0.15 per unit for gross proceeds of $1.6 million.
|
|
September 18 2008
Dr. Andrew Zhu joins Chemokine Dr. Andrew Zhu joins Chemokine Therapeutics Corp.’s Oncology Clinical Advisory Board. Comprised of leading oncologists, the Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.
|
|
September 17 2008
SFU and South Korean university sign collaborative research deal Simon Fraser University and South Korea’s Yonsei University sign a pair of agreements that will advance collaborative research in the areas of materials science and medicinal chemistry – and build on an existing relationship that promises many new and unique opportunities for exchanges and collaborations.
|
|
September 15 2008
Amorfix provides corporate update on regulatory processes and manufacturing Amorfix Life Sciences announces an update on the regulatory process in the European Union (EU) and manufacturing for vCJD blood screening tests.
|
|
September 15 2008
OncoGenex Pharmaceuticals announces out-license OncoGenex Pharmaceuticals, Inc. has granted to Eagle Pharmaceuticals, Inc. the exclusive worldwide rights to develop and commercialize TOCOSOL(R) Paclitaxel. Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future TOCOSOL Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received by Eagle Pharmaceuticals.
|
|
September 12 2008
ViRexx announces results of rights offering and failure of LM Funds Corp. to provide standby commitment ViRexx Medical Corp. announces that LM Funds Corp., the standby guarantor under its previously announced rights offering, has failed to fulfill its obligation to provide $3,000,000 CA as the Standby Purchaser for the rights offering.
|
|
September 12 2008
ARIUS announces leading independent proxy firm recommends shareholders vote regarding its acquisition by Roche ARIUS Research Inc. releases that RiskMetrics ISS Canada, Canada's leading independent proxy firm, has indicated that they have no objection to the transaction, and are recommending that ARIUS shareholders and warrant holders vote FOR the proposed plan of arrangement whereby Roche will acquire all of ARIUS' outstanding shares and warrants.
|
|
September 05 2008
Healthscreen announces management change Healthscreen Solutions Inc. announces that one of its current advisors, Ken Killin, will be appointed chief financial officer effective Sept. 19, 2008. Killin replaces Eugene Bomba, who will be leaving his position to return to private practice.
|
|
August 29 2008
Inflazyme completes non-brokered private placement Inflazyme Pharmaceuticals Ltd. announces that the non-brokered private placement for $300,000 announced on June 12, 2008 is now complete.
|
|
August 29 2008
Technology Triangle Inc. welcomes John G. Jung as new CEO John Doherty, chair of the Board of Canada's Technology Triangle Inc (CTT Inc), the public-private regional economic development partnership for Waterloo Region, is announces that John G. Jung will be joining CTT Inc as the new chief executive officer, effective September 22, 2008.
|
|
August 29 2008
Isotechnika hires advisors to advance strategic alternatives Isotechnika Inc. announces that its board of directors has approved the engagement of Leerink Swann LLC and Deloitte to advise the company as it pursues available strategic alternatives to enhance shareholder value.
|
|
August 29 2008
Biovail appoints Peggy Mulligan as chief financial officer Biovail Corporation appoints Peggy Mulligan, FCA as chief financial officer, effective Sept. 3, 2008.
|
|
August 29 2008
Methanex Corporation appoints Robert Kostelnik to its board Methanex Corporation appoints Robert Kostelnik to its board of directors effective immediately.
|
|
August 29 2008
CV Technologies appoints CFO CV Technologies Inc. appoints Allan Cleiren as chief financial officer, effective immediately. He replaces Nazir Noormohamed who has been interim CFO since March 28, 2008.
|
|
August 27 2008
Patheon establishes headquarters and development services laboratory Patheon selects locations in Research Triangle Park (RTP) and Durham, North Carolina for its global headquarters and new analytical development laboratory facilities.
|
|
August 27 2008
Transition Therapeutics announces executive management appointments Transition Therapeutics Inc. announces that Elie Farah has been appointed president in addition to continuing to serve as chief financial officer and Nicole Rusaw-George has been appointed to the position of vice president, Finance.
|
|
August 27 2008
Allon Therapeutics completes $20 million offering of common shares Allon Therapeutics Inc. announces it has completed a bought deal public offering of common shares first announced in its press release dated June 23, 2008.
|
|
August 27 2008
Dealmakers BioSyntech Inc. (Laval, QC)
Patheon Inc. (Mississauga, ON) Healthscreen Solutions Inc. (Toronto, ON) Microbix Biosystems Inc. (Toronto, ON) |
|
August 26 2008
Mark Redmond leaves Ceapro as president and CEO Biotech firm Ceapro Inc. announces that president and CEO Mark Redmond is leaving the company effective immediately.
|
|
August 26 2008
Calgary Scientific Inc. receives investment for new medical software suite Calgary Scientific Inc. (CSI) has received a $1 million investment from AVAC Ltd.’s new IVAC fund allowing it to speed-up the release of its suite of medical diagnostic software.
|
|
August 26 2008
Development milestone for Adnavance triggers $1.8M in financing Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announces it met a milestone in progressing its metalized DNA (M-DNA™) technology platform toward a new MRSA diagnostic test.
|
|
August 26 2008
World-famous stem cell scientist to work with Ontario Named last year by Time magazine as making the top scientific discovery in the world for his work in transforming human skin cells into stem cells, Dr. Shinya Yamanaka is bringing his expertise to Ontario to work with some of province’s leading stem cell researchers.
|
|
August 26 2008
Theratechnologies and PDC Biotech GmbH sign license agreement Montreal’s Theratechnologies announces an exclusive license agreement with PDC Biotech GmbH of Vienna, Austria for Theratechnologies’ family of antagonists of the prostaglandin F2a receptor used in preterm labour and primary dysmenorrhea.
|
|
August 22 2008
Calgary’s Userful Corporation receives $1 million investment to green the world’s computer industry A Calgary-based software company that helped its customers cut global CO2 emissions by more than 29,000 tonnes over the last 12 months (the environmental equivalent of taking 5,000 cars off the road), is preparing to ramp-up sales of its ecologically-friendly software that’s already revolutionized over 30,000 public and private desktops worldwide.
|
|
August 22 2008
U of S $50,000 BioVenture Challenge Business Plan competition launched The University of Saskatchewan (U of S) Industry Liaison Office (ILO) and Saskatchewan Agriculture are partnering to offer the 2008 BioVenture Business Plan Challenge to assist youth with launching their bio-based business ideas.
|
|
August 19 2008
CV Technologies reports third quarter results CV Technologies Inc. reports fiscal 2008 third quarter sales of $3.4 million, up 4.4% from sales of $3.2 million in the same quarter last year.
|
|
August 19 2008
Æterna Zentaris announces appointment of Prof. Jürgen Engel, Ph.D. as new president and CEO Æterna Zentaris Inc. appoints Prof. Jürgen Engel, Ph.D. as its new president and CEO, effective as of Sept. 1, 2008. Prof. Engel is currently executive vice president and chief scientific officer of Æterna Zentaris.
|
|
August 19 2008
YM Biosciences announces staffing changes YM BioSciences Inc. announces staff changes designed to focus the company on the international opportunities for both of its lead products, nimotuzumab and AeroLEF.
|
|
August 14 2008
ProMetic reaches understanding for commercialization of several biopharmaceutical products ProMetic Life Sciences Inc. reaches an understanding with a fully integrated, U.S.-based, biotechnology company with respect to the development and global commercialization of several biopharmaceutical products in ProMetic's Protein Technology Division.
|
|
August 14 2008
Inflazyme Pharmaceuticals receives conditional approval of private placement from NEX Inflazyme Pharmaceuticals Ltd. receives conditional approval from NEX on its recently announced $300,000 non-brokered private placement (the "Offering").
|
|
August 12 2008
Government invests over $13.6 million in Vancouver's fuel cell industry The Government announces a $13.6 million investment in the National Research Council (NRC)'s Vancouver-based fuel cell and hydrogen industry and officially opened the Hydrogen and Fuel Cell Gateway - a technology demonstration and exhibit centre showcasing Canada's world-leading fuel cell and hydrogen industry.
|
|
August 12 2008
Government announces $9.37 million investment in 13 technology development projects The Honourable Diane Ablonczy, Secretary of State (Small Business and Tourism), on behalf of the Honourable Jim Prentice, Minister of Industry, and Dr. Martin Godbout, president and CEO of Genome Canada, announce $9.37 million in funding for the winners of the Genome Canada Technology Development Competition.
|
|
August 12 2008
E.coli detection development company sets up in Waterloo, ON Early Warning Inc, a developer of early warning systems that detect E.coli and other biohazards announces the opening of its Water Products Division in Waterloo, ON.
|
|
August 12 2008
Dealmakers Protez Pharmaceuticals (Malvern, PA) and Novartis have reached an agreement that will see Novartis (Basel, Switzerland) acquire Protez. Under the terms of the agreement, Novartis will acquire Protez for up to $400 million in cash, which $100 million will be paid at closing and up to $300 million will be paid if certain clinical milestones, regulatory approvals and commercial targets are achieved.
|
|
August 12 2008
Dr. Nancy Edwards appointed new scientific director of CIHR's Institute of Population and Public Health Dr. Pierre Chartrand, acting president of the Canadian Institutes of Health Research (CIHR), along with CIHR's Governing Council, announces the appointment of Dr. Nancy Edwards as incoming scientific director of CIHR's Institute of Population and Public Health (IPPH).
|
|
August 12 2008
Urodynamix appoints vice president of business development Urodynamix Technologies Ltd. appoints Greg Gauthier as vice president of Business Development.
|
|
August 12 2008
Medicure appoints new CFO Medicure Inc. appoints Dwayne Henley as its new chief financial officer.
|
|
August 06 2008
Canada - China partnership aims to increase oil yield of canola The National Research Council Canada (NRC) and the Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences sign an agreement to collaborate on genetic research to improve the production of canola.
|
|
August 06 2008
Monsanto Canada announces new appointments Monsanto Canada announces several appointments in its canola and crop protection marketing group.
|
|
August 05 2008
Inflazyme Pharmaceuticals receives conditional approval of private placement from NEX Inflazyme Pharmaceuticals Ltd. receives conditional approval from NEX on its recently announced $300,000 non-brokered private placement (the "Offering).
|
|
August 01 2008
Canadian Pain Society, mdBriefCase and AdvancingIn team up The Canadian Pain Society (CPS), AdvancingIn and mdBriefCase Inc. partner to provide on-line education and support for Canadian healthcare professionals involved in pain management.
|
|
August 01 2008
Monsanto Canada appoints new president, general manager Monsanto Canada announces the appointment of Lisa Safarian to the position of president and general manager of its Canadian business operations.
|
|
July 24 2008
ARIUS announces second quarter fiscal 2008 financial results ARIUS Research Inc. announces its financial and operational results for the second fiscal quarter of 2008, ended May 31st, 2008.
|
|
July 23 2008
Government invests $25 million in biofuels production Suncor Energy’s St. Clair Ethanol Plant is expanding to double its production of cleaner-burning, renewable energy, thanks to a $25 million investment by the Government of Canada.
|
|
July 23 2008
BioSyntech completes $11 million bought deal BioSyntech, Inc. closes its previously announced bought deal.
|
|
July 23 2008
FRSQ, INSERM and CIHR sign a France-Quebec-Canada partnership The health research funding organizations of Quebec (the Fonds de la recherche en santé du Québec, FRSQ), France (the Institut national de la santé et de la recherche médicale, Inserm) and Canada (the Canadian Institutes of Health Research's Institute of Neurosciences, Mental Health and Addiction, and Institute of Aging) sign a co-operation agreement on Alzheimer's disease research.
|
|
July 18 2008
Inflazyme Pharmaceuticals Ltd. aAnnounces financial results for the year ended Inflazyme Pharmaceuticals Ltd. reports its financial results for the year ended March 31, 2008. The net loss for the year ended March 31, 2008 was $227,000 ($0.00 per common share) compared to a net loss of $15,384,000 ($0.13 per common share) for the prior year.
|
|
July 07 2008
WEX appoints chief financial officer WEX Pharmaceuticals Inc. announces the promotion of Kwong Choo to the position of chief financial officer and vice president, Finance and Administration effective July 1, 2008. He has served as controller since January 2008.
|
|
July 07 2008
Inflazyme Pharmaceuticals announces escrow closing of private placement Inflazyme Pharmaceuticals Ltd. closes in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant").
|
|
July 07 2008
Genome Prairie announces new president and CEO Dr. Arnold Naimark, chair of Genome Prairie's board of directors, appoints Dr. Wilf
Keller as the new president and CEO of Genome Prairie. |
|
July 07 2008
Ceapro expands its markets for organic natural active ingredients into South Korea Ceapro Inc. announcs the completion of a new marketing partnership and distribution agreement with Korean firm, East Hill Corporation.
|
|
July 07 2008
Haemacure appoints two new senior managers Haemacure Corporation announces the appointment of two senior managers to its management team.
|
|
July 07 2008
Warnex Inc. (Laval, QC) Warnex Inc. (Laval, QC), signs an agreement with Desjardins Group, the largest financial cooperative in Canada, for financing and banking services.
|
|
July 07 2008
Protex Therapeutics Inc. (Vancouver, BC.) Protex Therapeutics Inc. (Vancouver, BC), announces that it intends to raise up to $3 million through a private placement of common shares of the company at a price of $0.70 per share.
|
|
July 07 2008
Med BioGene Inc. (Vancouver, BC) Med BioGene Inc. (Vancouver, BC) and the University Health Network (UHN) enter into license and collaboration agreement providing MBI with exclusive, world-wide rights to develop and commercialize a critical prognostic test for early stage non-small-cell lung cancer developed by UHN.
|
|
July 07 2008
ProMetic Life Sciences Inc. (Montreal, QC) ProMetic Life Sciences Inc. (Montreal, QC) provides an update on its business activities.
|
|
July 07 2008
Urodynamix Technologies Ltd. and Laborie Medical Technologies (Vancouver, BC) Urodynamix Technologies Ltd. and Laborie Medical Technologies (Vancouver, BC) announce the U.S. launch of the Tetra™ Bladder monitoring System, a catheter-free medical device that uses near infrared spectroscopy (NIRS) to aid in the diagnosis of lower urinary tract symptoms (LUTS).
|
|
July 07 2008
Covalon Technologies Ltd. (Mississauga, ON) Covalon Technologies Ltd. (Mississauga, ON) receives approval from the Therapeutic Product Directorate at Health Canada to begin marketing the corporation’s proprietary products: BIOSTEP™ Collagen Matrix Dressing and BIOSTEP™ Ag Collagen Matrix Dressing with Silver.
|
|
July 04 2008
Medical Ventures becomes Neovasc with two corporate acquisitions and $8.3 million financing Neovasc Inc., formerly Medical Ventures Corp., a company developing and marketing innovative specialty vascular devices, announces its name change and the expansion of its product portfolio, as the company completed the acquisition of two vascular product development companies and the closing of an $8.3 million private financing.
|
|
July 04 2008
Inflazyme announces proposed merger with Z-Tech terminated Inflazyme Pharmaceuticals Ltd. announces that its proposed merger with Z-Tech will not go forward. The merger agreement provided for an outside date to complete the merger by April 11, 2008. The conditions to the merger were not satisfied and the agreement has therefore terminated.
|
|
June 27 2008
OCE forms strategic partnership with Let’s Talk Science Ontario Centres of Excellence (OCE) has formed a strategic partnership with Let's Talk Science (LTS), to work towards building the 'talent pipeline' and developing a culture of innovation in Ontario.
|
|
June 23 2008
Canada and India announce joint science and technology initiatives The Honourable David Emerson, Minister of Foreign Affairs and International Trade and Minister for the Pacific Gateway and the Vancouver-Whistler Olympics, and the Honourable Kapil Sibal, India’s Union Minister of Science & Technology and Earth Sciences, announce the launch of 10 new Canada-India science and technology (S&T) joint initiatives worth $17 million.
|
|
June 23 2008
Urodynamix appoints vice president of business development Urodynamix Technologies Ltd. appoints Greg Gauthier as vice president of Business Development.
|
|
June 23 2008
Theratechnologies comments on current market activity In the context of the current market activity and the recent positive clinical results, Theratechnologies confirms that its strategic review process is still active and ongoing and that it is entertaining discussions with a number of companies at this time.
|
|
June 20 2008
Atlantic Canada showcases its talents at Bio 2008 The Atlantic Canada Bio-Industries Alliance led a strong delegation to Bio 2008 in San Diego, CA, this year, with help from the federal and provincial governments under the Canada/Atlantic Provinces Agreement on International Business Development (IBDA).
|
|
June 20 2008
Canada and India announce joint science and technology initiatives The Honourable David Emerson, Minister of Foreign Affairs and International Trade and Minister for the Pacific Gateway and the Vancouver-Whistler Olympics, and the Honourable Kapil Sibal, India’s Union Minister of Science & Technology and Earth Sciences, announce the launch of 10 new Canada-India science and technology (S&T) joint initiatives worth $17 million.
|
|
June 20 2008
Med BioGene expands Lymphoma collaboration with Duke University Med BioGene announces that it has expanded its lymphoma collaboration with Duke University Medical Center to include Northwestern University, Indiana University and the University of Hong Kong. Discussions are currently underway with other leading universities who are expected to join the working group.
|
|
June 20 2008
Patheon unveils new brand image Patheon unveils its new brand image. The new brand features a new logo, new company colours and a new slogan that reflect Patheon's vision to become the best provider of manufacturing and development services to the pharmaceutical industry.
|
|
June 13 2008
Government highlights science and technology linkages with Chile The Honourable Jim Prentice, Minister of Industry and Minister responsible for the National Research Council of Canada (NRC), gave Her Excellency Michelle Bachelet, President of the Republic of Chile, an overview of Canada's Science and Technology Strategy and how innovative partnerships with industry, universities and international partners are providing Canadian businesses with targeted research and groundbreaking discoveries for commercial development.
|
|
June 09 2008
BC Advantage Funds portfolio company goes public BC Advantage Funds announces that one of its portfolio companies, Protiva Biotherapeutics went public on June 2, 2008 by way of a reverse merger with Tekmira Pharmaceuticals.
|
|
June 09 2008
Stem Cell Therapeutics Corp. expands executive team Stem Cell Therapeutics Corp. appoints Thomas Franck as vice president of Commercial Planning.
|
|
June 06 2008
Canada and China announce new joint science and technology initiatives The Honourable David Emerson, Minister of International Trade and Minister for the Pacific Gateway and the Vancouver-Whistler Olympics, announces the launch of 20 new Canada-China science and technology (S&T) joint initiatives.
|
|
June 06 2008
New director joins Viterra's board Viterra Inc. announces that T.J. (Tim) Hearn will join Viterra's Board of Directors effective immediately. Hearn will serve on Viterra's Audit Committee.
|
|
June 06 2008
Protox completes $4.8 million private placement Protox Therapeutics Inc. closes its previously announced private placement of common shares at a price of $0.70, resulting in gross proceeds to the company of approximately $4.8 million.
|
|
June 06 2008
International Health Partners Inc. to seek approval to sell dental clinics International Health Partners Inc. announces that it is submitting for review to the TSX Venture Exchange a draft information circular with respect to a proposed Annual and Special Meeting (the"IC"), at which shareholders will be asked to approve (i) the sale of its five dental clinics to Altima Dental Canada Inc. ("Altima") for a purchase price of $956,000.
|
|
May 30 2008
Med BioGene appoints diagnostics industry veteran – Dr. Heiner Dreismann to board of directors Med BioGene Inc. announces that Heiner Dreismann, Ph.D., has joined the company’s board of directors and will chair MBI’s Strategy Committee. Dr. Dreismann is the former chief executive officer of Roche Molecular Diagnostics (Roche), a division of F. Hoffmann-La Roche Ltd.
|
|
May 27 2008
Patheon makes executive management appointments Patheon Inc. announcesthe following executive management appointments: Eric W. Evans as chief financial officer of Patheon Inc.; Paul M. Garofolo as senior vice President and chief information officer; Warren A. Horton as vice president Global Quality Operations; and Doaa A. Fathallah as senior vice president, General Counsel Europe and Global Pharmaceutical Development Services.
|
|
May 27 2008
Dan Casey becomes Sonomax chief executive officer Sonomax Hearing Healthcare Inc. announces that Dan Casey is the chief executive officer of the company effective immediately, replacing Barry Schwartz. Schwartz will remain the non-executive chairman of the board of the corporation.
|
|
May 23 2008
Global report cites Canadian biotech funding crisis: Ernst & Young Venture financing in the private Canadian biotechnology sector shot up 72% in 2007, but the surge may be indicative of wider issues, Ernst & Young reveals in Beyond borders: Global biotechnology report 2008.
|
|
May 21 2008
Manitoba lab has new director TRLabs appoints Len Dacombe, an executive with 28 years of technology leadership experience, as director Manitoba operations.
|
|
May 21 2008
Axela expands board of directors to support growth Axela Inc. expands its board of directors as the company positions itself for growth in the diagnostic, life science, and pharmaceutical research markets.
|
|
May 21 2008
ProMetic Life Sciences Inc. (Montreal, QC) ProMetic Life Sciences Inc. (Montreal, QC) announces filing of a Supplement (the "Supplement") to a short form base shelf prospectus of ProMetic (the “Prospectus”) that was previously filed on November 3, 2006.
|
|
May 21 2008
MethylGene Inc. (Montreal, QC) and EnVivo Pharmaceuticals MethylGene Inc. (Montreal, QC) and EnVivo Pharmaceuticals announce that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005.
|
|
May 21 2008
AIM Therapeutics Inc. (Toronto, ON) AIM Therapeutics Inc. (Toronto, ON) release that the company’s asthma program has entered the next phase of development towards the clinic.
|
|
May 21 2008
ProMetic Life Sciences Inc. to raise up to C$5 M ProMetic Life Sciences Inc. announces the filing of a Supplement (the “Supplement”) to a short form base shelf prospectus of ProMetic (the “Prospectus”) that was previously filed on November 3, 2006
|
|
May 21 2008
AEterna Zentaris and Paladin Labs complete sale and purchase of Miltefosine rights AEterna Zentaris Inc. and Paladin Labs Inc. announce that on March 31, 2008, it completed the transactions under its previously announced purchase and sale agreement with respect to all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine.
|
|
May 15 2008
Cancer receives more than $700,000 in new funding Three researchers working in the areas of identifying early indicators of colorectal cancer risk and genetic cause of the disease and looking at the impact in Ontario of new clinical guidelines for treating head and neck cancers will receive more than $700,000 in new funding from the Canadian Cancer Society.
|
|
May 09 2008
Protox announces collaboration with FDA Protox Therapeutics Inc. announces that it has collaborated with the U.S. Food and Drug Administration (FDA) under the terms of a Cooperative Research and Development Agreement (CRADA).
|
|
May 09 2008
QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc. QSV Biologics, Ltd. has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV’s Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.
|
|
May 01 2008
Neuromed names Sean Cunliffe chief commercial officer Neuromed Pharmaceuticals announces the promotion of Sean Cunliffe to chief commercial officer. Cunliffe will lead all pre- and post-approval commercial activities of Neuromed's product candidates, including NMED-1077 (OROS(R) Hydromorphone) in Phase III clinical development for the treatment of moderate-to-severe chronic pain.
|
|
May 01 2008
Med BioGene and University Health Network collaborate to commercialize critical lung cancer prognostic test Med BioGene Inc. and the University Health Network (UHN) enter into a license and collaboration agreement providing MBI with exclusive, world-wide rights to develop and commercialize a critical prognostic test for early stage non-small-cell lung cancer developed by UHN.
|
|
April 25 2008
Accucaps announces new developments for health and nutritional soft gel manufacturing Accucaps Industries Ltd. converted its newest facility in Strathroy to focus on the production of Health & Nutritionals (H&N) and cosmetic products.
|
|
April 25 2008
Holmes Biopharma awarded 1.2 millon dollar contract Holmes Biopharma Inc. announces the signing of a 1.2 million dollar contract with a large East Asian pharmaceutical company.
|
|
April 25 2008
Inflazyme announces proposed merger with Z-Tech terminated Inflazyme Pharmaceuticals announces that its proposed merger with Z-Tech will not go forward. The merger agreement provided for an outside date to complete the merger by early April.
|
|
April 25 2008
Vernalis and Paul Capital Healthcare sign financing agreement Vernalis and Paul Capital Healthcare announce that they have signed a financing agreement relating to frovatriptan, Vernalis’ product for the treatment of migraine.
|
|
April 25 2008
Battelle Ventures invests in DNA-analysis company BioNanomatrix Battelle Ventures leads the $5.1 millon funding round of BioNanomatrix, Inc., a company developing and commercializing nanoscale, single-molecule imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome.
|
|
April 18 2008
SciCan Ltd. to distribute HMDT plasma sterilizers in Canada SciCan Ltd signs an agreement with HMDT of Seoul, South Korea to distribute HMDT plasma sterilizers to Canadian hospitals.
|
|
April 11 2008
Urodynamix announces first commercial product shipment Urodynamix Technologies Ltd. announces that it has successfully completed a major program milestone by making the first commercial shipment of Tetra™ Bladder Monitor Systems to its worldwide distribution partner, Laborie Medical Technologies, in the first quarter of 2008.
|
|
April 11 2008
Lorus Therapeutics announces exclusive multinational license agreement with Zoticon Bioventures Lorus Therapeutics Inc. announces that its subsidiary GeneSense Technologies, Inc. has signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC formed as a subsidiary of Zoticon Bioventures Inc., a research-driven biopharmaceutical group, to further develop and commercialize Virulizin(R) for human therapeutic applications.
|
|
April 11 2008
MethylGene announces worldwide research collaboration and license agreement MethylGene Inc. announces a worldwide research collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd., a global pharmaceutical company, for the development of novel, small molecule, kinase inhibitors for the local delivery and treatment of ocular diseases, excluding cancer.
|
|
April 11 2008
Æterna Zentaris announces changes to its management team Æterna Zentaris Inc. announces that David J. Mazzo, Ph.D., has resigned as president and chief executive officer and as member of the board of directors of Æterna Zentaris, effective immediately.
|
|
April 04 2008
Biovail announces resignation of director Jamie Sokalsky Biovail Corporation announces that Jamie Sokalsky has tendered his resignation from the company's board of directors.
|
|
April 04 2008
Titanium Corporation receives $3.5 million grant from the Province of Alberta Titanium Corporation Inc. has been awarded a $3.5 million Energy Innovation Fund Grant from the Province of Alberta to allow the company to continue its research into the value-added opportunities and environmental benefits of recovering hydrocarbons and heavy minerals from mined oil sands tailings.
|
|
March 31 2008
Ceragenix enters into agreement to license CSA-54 for HIV and STD applications Ceragenix Pharmaceuticals Inc. enters into an agreement to license CSA-54 and other Ceragenin compounds to FirstPoint Biotech for HIV and STD applications.
|
|
March 31 2008
PharmAthene signs definitive agreement to acquire biodefense vaccines business PharmAthene Inc. signs a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia’s biodefense vaccines business.
|
|
March 31 2008
CV Technologies is set for growth CV Technologies' recent financial and operational performance sets the stage for successful long-term growth through product line and geographic diversification, said president, CEO and chief scientific officer Dr. Jacqueline Shan.
|
|
March 31 2008
Urodynamix announces second collaboration for development of NIRS prostrate treatment device Urodynamix Technologies announces that it has initiated a second collaborative program for the evaluation of a transurethral microwave thermotherapy (TUMT) device incorporating NIRS technology.
|
|
March 31 2008
Generex receives purchase order for 210,000 canisters of Oral-lyn Generex receives purchase order for 210,000 canisters of Generex Oral-lyn, the company’s proprietary oral insulin spray product.
|
|
March 31 2008
Accentia Biopharmaceuticals announces results on primary endpoint in clinical study of SinuNase Lavage Accentia Biopharmaceuticals, Inc. announces that its Phase III clinical trial evaluating the company’s exclusively-licensed technology from the Mayo Clinic consisting of an intranasal antifungal lavage, SinuNase™ (topical amphotericin B 0.01% suspension) achieved, as anticipated, superior resolution of the cardinal symptoms of chronic sinusitis (CS).
|
|
March 31 2008
Quebec Superior Court issues final order approving the acquisition of Axcan by an affiliate of TPG Capital Axcan Pharma Inc. announces that the Superior Court of Quebec has issued a final order approving the Plan of Arrangement pertaining to the acquisition by an affiliate of TPG Capital of all outstanding common shares of Axcan.
|
|
March 31 2008
Correction Notice Please note the following correction in the story Migenix Takes Products: From Conception to Commercialization, found in the February 2008 issue of Biotechnology Focus.
|
|
March 31 2008
Dealmakers Patheon Inc. (Toronto, ON) completes the previously announced sale of its Niagara-Burlington commercial manufacturing business to Pharmetics Inc., under the same terms as previously disclosed.
|
|
March 25 2008
Cepheid receives Health Canada Medical Device License Health Canada has issued Cepheid a medical device license for the Xpert™ MRSA test for the rapid detection of Methicillin Resistant Staphylococcus aureus (MRSA) on nasal swabs and the GeneXpert® System.
|
|
March 25 2008
Canada's Technology Triangle Inc welcomes Shelley Rudd Shelley Rudd has joined Canada’s Technology Triangle Inc. (CTT Inc) in the position of manager, Marketing and Communications.
|
|
March 25 2008
BIOCAP closes its doors BIOCAP Canada recently announced its dissolution, marking the end of a decade of building multi-sector partnerships and delivering scientific insights and new technologies to aid Canada's transition to a bioeconomy.
|
|
March 25 2008
CV Technologies appoints two new directors CV Technologies Inc. appoints two new members to its board of directors.
|
|
March 25 2008
DiagnoCure appoints chief financial officer DiagnoCure Inc. appoints Jean François Bureau, CFA, as chief financial officer. Bureau’s experience spans over nearly 20 years in the North American and European financial markets.
|
|
March 25 2008
Monsanto’s Roundup Ready 2 yield soybeans receive key approvals in Asia Monsanto Company receives final regulatory approval in Japan, the Philippines and Taiwan for its second-generation soybean technology, Roundup Ready 2 YieldTM (MON 89788).
|
|
March 25 2008
Viterra appoints new chief financial officer Viterra appoints Rex McLennan as chief financial officer, effective immediately.
|
|
March 20 2008
Spectral appoints Anthony Bihl to board of directors Spectral Diagnostics Inc. announces that Anthony Bihl has been appointed to the company's board of directors.
|
|
March 20 2008
Lilly and Transition Therapeutics announce licensing and collaboration agreement Eli Lilly and Company and Transition Therapeutics Inc. announces that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.
|
|
March 14 2008
Laborie Medical Technologies receives FDA clearance for Tetra™ Bladder Monitor System Laborie Medical Technologies receives FDA clearance for Tetra(TM) Bladder Monitor System, paving the way for approval of the commercial launch of Urodynamix’s NIRS technology for non-invasive bladder testing.
|
|
March 14 2008
DNA Testing Systems inks agreement with DNAPrint Genomics DNA Testing Systems signs an agreement to sell DNAPrint Genomics' line of biogeographical ancestry tests.
|
|
March 07 2008
Toronto Centre for Phenogenomics appoints CEO The Toronto Centre for Phenogenomics (TCP) appoints Dr. Colin McKerlie as chief executive officer.
|
|
March 07 2008
Mistral Pharma signs distribution agreement for six products Mistral Pharma Inc. signs a distribution agreement with an undisclosed pharmaceutical company for six injectable generic products for the Canadian market.
|
|
March 07 2008
Correction notice to February 2008 Executive Profile Correction notice to the article “Migenix Takes Products from Conceptualization to Commercialization” in the February 2008 issue of Biotechnology Focus.
|
|
March 03 2008
ProMetic signs agreement with Kedrion for two hyperimmune products ProMetic Life Sciences Inc. signs a definitive license agreement for the development of two hyperimmune products with Kedrion S.p.A.
|
|
March 03 2008
Inflazyme and Z-Tech receive interim court order regarding potential merger Inflazyme Pharmaceuticals Ltd. and Z-Tech Inc. each receive interim court order for the calling and conduct of the special meetings of securityholders to consider the merger between Inflazyme and Z-Tech.
|
|
March 03 2008
Paladin Labs & KV Pharmaceuticals sign distribution for Micro-K® Extencaps® Paladin Labs Inc. and KV Pharmaceuticals enter into an exclusive Canadian Distribution Agreement with for Micro-K(R) Extencaps(R) capsules.
|
|
February 28 2008
Ambrilia announces departure of Dr. Chandra J. Panchal Ambrilia Biopharma Inc. announces the departure of Dr. Chandra J. Panchal as executive vice-president, Business Development, Licensing and Intellectual Property, effective March 1, 2008. Dr. Panchal will continue to serve as senior adviser to the president and CEO, on a per project basis, until Dec. 31, 2008.
|
|
February 28 2008
ART announces first sale of SoftScan® optical breast imaging system Toronto's Sunnybrook Health Sciences Centre chooses SoftScan® as the right fit for its expanding breast imaging program.
|
|
February 28 2008
Axcan announces completion of transaction with TPG capital Axcan Pharma Inc. announces the completion of the transaction in which all of the common shares of Axcan have been acquired by an affiliate of TPG Capital.
|
|
February 22 2008
Viterra and Evogene to develop canola with improved yield and stress tolerance traits Viterra and Evogene Ltd. announce a joint collaboration to develop canola with improved yield and tolerance to abiotic stress. Under the three-year collaboration, the companies will assess a number of Evogene discovered gene candidates in trials involving Viterra's elite canola lines. These varieties will be evaluated under normal and stress conditions.
|
|
February 22 2008
Supreme Court of Canada denies leave to appeal in Saskatchewan organic case The Supreme Court of Canada denies the application for Leave to Appeal in the case of Larry Hoffman, L.B. Hoffman Farms Inc. and Dale Beaudoin vs. Monsanto Canada and Bayer CropScience Inc.
|
|
February 22 2008
AllerGen, TOPIGEN partner to provide hands-on training to post-doctoral, MD grads AllerGen NCE Inc. and TOPIGEN Pharmaceuticals Inc. are offering recent doctoral graduates and MD clinician scientists the opportunity to gain valuable experience in research and development in an industrial setting.
|
|
February 22 2008
Bioniche receives $5 million to scale-up vaccine production in Ontario Bioniche Life Sciences Inc. has received $5 million in federal government financing in support of its vaccine production facility scale-up in Belleville, ON.
|
|
February 22 2008
Bioniche Life Sciences Inc. (Belleville, ON) Bioniche Life Sciences Inc. (Belleville, ON) announces that the company has renewed and amended the terms of its long-term convertible debt with Laurus Master Funds.
|
|
February 22 2008
Genizon BioSciences (Montreal, QC) Genizon BioSciences (Montreal, QC) secures $31 million in additional financing funding for genome-wide association studies in metabolic syndrome and coronary artery disease.
|
|
February 22 2008
Agriculture and Agri-Food Canada and the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Spain Agriculture and Agri-Food Canada and the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Spain sign a Letter of Intent on agriculture and agri-food research interests as a further confirmation of cooperation between the two countries.
|
|
February 22 2008
Eli Lilly and BioMS Medical announce global licensing and development agreement Eli Lilly and company and BioMS Medical Corp. have entered into a licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical’s lead multiple sclerosis (MS) compound, MBP8298.
|
|
February 22 2008
Amorfix appoints a member of board of directors Amorfix Life Sciences appoints Aziz Mekouar to the company's board of directors.
|
|
February 22 2008
GeneNews appoints three leading cancer screening experts GeneNews Limited appoints three additional members to its Colorectal Cancer (CRC) Clinical Advisory Board.
|
|
February 22 2008
Transition Therapeutics included in the NASDAZ global market Transition Therapeutics Inc. announces that its common shares have been approved for listing and began trading on the NASDAQ Global Market on Jan. 7, 2008.
|
|
February 15 2008
BMO releases economic report for Waterloo-Guelph region The Waterloo Region and Guelph area is “one of the brightest stars in the Canadian economic skies,” according to a new report published by BMO Financial Group and Canada’s Technology Triangle Inc. Keeping the region’s economy shining brightly will be challenging in the short term because of the manufacturing sector dealing with a strong Canadian dollar and weakening U.S. demand. However, the area’s economy should show strong growth by 2009.
|
|
February 15 2008
Genizon BioSciences collaborates with London Genetics to enhance gene discovery findings in schizophrenia Genizon BioSciences Inc. and London Genetics Ltd announce an agreement under which they will collaborate to replicate discoveries made by Genizon in a genome-wide association study of schizophrenia. Genizon's study identified multiple genes associated with the disease using DNA samples from the Quebec Founder Population.
|
|
February 15 2008
CLINICARE and Barrie FHT sign EMR contract CLINICARE Corporation of Calgary announces that it has been selected by the Barrie and Community Family Health Team to implement their OntarioMD approved Clinical Management Solution (CMS).
|
|
February 15 2008
ProMetic discloses terms of Millipore agreement ProMetic Life Sciences Inc. enters into a binding agreement with Millipore Corporation being executed in two phases; the initial license and the subsequent long-term license.
|
|
February 15 2008
Royalty Pharma and InNexus Biotechnology announce purchasing agreement Royalty Pharma and InNexus Biotechnology announce an agreement regarding the purchase of a second royalty right based on InNexus Dynamic Cross Linking (DXL™) antibody technology.
|
|
February 15 2008
Thallion agrees with FDA on further development of Shigamabs® Thallion Pharmaceuticals Inc. announces an agreement with the U.S. Food and Drug Administration (FDA) in respect of the company’s Shigamabs® program for the treatment of Shigatoxin-mediated E. coli infections.
|
|
February 07 2008
Biovail receives letter related to 2003 Cardizem(R) LA Launch Biovail Corporation has been notified by the United States Attorney's Office in Boston, MA, that the corporation is the target of a federal grand jury investigation in connection with activities surrounding the 2003 commercial launch of Cardizem(R) LA.
|
|
February 07 2008
BioTalent Canada launches new website BioTalent Canada launches its new re-engineered website. The new site has been designed to ensure stakeholders have quick access to the information about projects, research, courses and tools in one integrated site.
|
|
January 30 2008
Despite record spending... According to Integrative Consulting Services, biotech and pharma companies spend four to 10 times more than other industries to manage contract vendors. With contract research organizations (CROs) involved in two-thirds of clinical trials, this inefficiency represents a huge waste of money and energy.
|
|
January 30 2008
Biotech veteran appointed to boost Alberta pharmaceutical start-ups TEC Edmonton and the Alberta Heritage Foundation for Medical Research (AHFMR) announce the appointment of Dr. Randall Yatscoff to position of new executive in residence.
|
|
January 30 2008
Patheon appoints Wesley P. Wheeler as chief executive officer Patheon Inc. welcomes pharmaceutical industry executive Wesley P. Wheeler to the company as its new chief executive officer.
|
|
January 30 2008
Dealmakers Bio-Extraction Inc. (Toronto, ON) concluded a Memorandum of Understanding with Viterra (Regina, SK) to enter into a definitive supply agreement for the supply of canola seed to the planned BioExx Saskatoon extraction facility.
|
|
January 24 2008
BioNova member companies have success in the fifth round of the Atlantic Innovation Fund Congratulations are being sent out to BioNova member companies and organizations on their success in the fifth round of the Atlantic Innovation Fund.
|
|
January 24 2008
Agrium's offer to purchase shares of UAP receives approval from the Canadian Commissioner of Competition Agrium Inc. announces that the Canadian Commissioner of Competition has issued a "no-action" letter in respect of Agrium's previously announced agreement for the acquisition of all of the outstanding common stock of UAP Holding Corp. by a wholly-owned subsidiary of Agrium.
|
|
January 24 2008
Viterra sees encouraging signs in agriculture Vittera confirms that it has received pre-payments of $250 million to date, approximately $100 million ahead of its expectations.
|
|
January 24 2008
Oncolytics Biotech announces issuance of 7th Canadian patent Oncolytics Biotech Inc. has been granted Canadian patent 2,508,238 entitled “Reovirus for the Treatment of Neoplasia.”
|
|
January 24 2008
EpiCept provides update on clinical and regulatory process with Ceplene and EpiCept NP-1 cream EpiCept Corporation announces that its Marketing Authorization Application (MAA) seeking marketing approval for Ceplene in the European Union has advanced to the next important step.
|
|
January 24 2008
Dalton Medicinal Chemistry Partners achieves another milestone Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved another targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
|
|
January 21 2008
Axela and VWR International sign a distribution agreement Axela Inc., a company specializing in protein interaction technology and VWR International, a leader in the research laboratory supply industry, announces that the two companies have entered into a distribution agreement for North America.
|
|
January 21 2008
Sigma-Aldrich signs agreement with Nanoco Technologies, Ltd. to distribute quantum dot nanocrystals Sigma-Aldrich signs an agreement with Nanoco Technologies, Ltd., a nano-materials company based in Manchester, UK, to distribute luminescent quantum dot nanocrystals globally.
|
|
January 21 2008
Thallion resolves dispute with CAP-232 licensor Thallion Pharmaceuticals Inc. announces the resolution of the outstanding dispute with its licensor of CAP-232, Expergen Drug Development GmbH of Austria.
|
|
January 21 2008
Dan Casey joins Sonomax as president and chief operating officer Sonomax Hearing Healthcare Inc. hires Dan Casey as president and chief operating officer. Casey was formerly executive vice president of Future Electronics.
|
|
January 21 2008
Protox appoints vice president, Business Development & Strategy Protox Therapeutics Inc. appoints Tom D’Orazio as vice president, Business Development and Strategy. D’Orazio is a pharmaceutical executive who brings 19 years of industry experience to Protox.
|
|
January 18 2008
Genizon Biosciences secures $31 million in additional financing Genizon BioSciences announces the closing of its Series E financing in the amount of $31 million. The lead investor is BTF B.V. of Haarlem, The Netherlands, a venture capital fund focused on late stage biotechnology companies.
|
|
January 11 2008
Well known business leaders to join MaRS board MaRS Discovery District announces the appointment of three well known business leaders to its board of directors: Geoffrey Matus, William White and Gordon Nixon.
|
|
January 11 2008
Allon Therapeutics confirms milestones for 2008 Allon Therapeutics Inc. confirms that its 2008 milestones include results from three Phase II human clinical trials that will indicate whether the company's drugs AL-108 and AL-208 have an effect on three of the most underserved diseases - Alzheimer's disease (AD), stroke and cognitive impairment associated with schizophrenia.
|
|
January 07 2008
Aegera and Human Genome announce collaboration agreement on novel anti-cancer drugs Aegera Therapeutics Inc. and Human Genome Sciences Inc. (HGS) announce an agreement under which HGS has acquired exclusive worldwide rights to develop and commercialize AEG40826 and related backup compounds to be chosen during a three-year research collaboration.
|
|
January 07 2008
Transition Therapeutics announces milestone payment from Elan Transition Therapeutics Inc. announces that the company will receive a US$5 million milestone payment under its global collaboration with a subsidiary of Elan Corporation.
|
|
January 07 2008
Agrium to re-file Hart-Scott-Rodino pre-merger notification Agrium Inc. announces that it has withdrawn its notification and report form submitted to the Antitrust Division of the U.S. Department of Justice and the Federal Trade Commission (FTC) under the Hart-Scott-Rodino Antitrust Improvements Act in connection with the previously announced acquisition of all of the outstanding common stock of UAP Holding Corp.
|
|
January 04 2008
Biovail announces supply agreement for commercialization of extended-release tramadol Biovail Corporation announces that its subsidiary, Biovail Laboratories International SRL, has entered into an exclusive supply agreement with Janssen Pharmaceutica NV, for the marketing and distribution of tramadol.
|
|
January 04 2008
Patheon announces agreement to sell Niagara-Burlington manufacturing business Patheon Inc. announces that it has entered into a definitive agreement to sell its Niagara-Burlington commercial manufacturing business to Quebec-based Pharmetics Inc.
|
|
December 21 2007
TRLabs appoints director of Saskatchewan Operations TRLabs announces the appointment of Dave Schroeder as director Saskatchewan Operations. The appointment is effective immediately.
|
|
December 21 2007
The Government of Canada invests $118 million in public-private S&T partnerships The Government of Canada reconfirms its support for R&D-based partnerships between all levels of government, the private sector and university researchers by investing $118 million over three years in six National Research Council (NRC) technology cluster initiatives.
|
|
December 18 2007
Government invests over $300,000 to boost health benefits of beef The Government of Canada is investing $305,792 towards bringing to the marketplace Canadian beef enhanced with bioactive lipids considered to be beneficial to human health.
|
|
December 18 2007
Covalon announces appointment of new CFO Covalon Technologies Ltd. appoints Francis K. Lindayen as chief financial officer of the company, effective immediately.
|
|
December 18 2007
Chemokine Therapeutics Announces New Directors Chemokine Therapeutics Corp. announces that Brian Kuhn, Bernard Byrd, George Kowalchuk and Reza Bahadori have joined the board of directors. They will fill vacancies created by the resignations of C. Richard Piazza, Michael Evans, John Osth and Matthias Kurth.
|
|
December 13 2007
SemBioSys appoints former Esperion officer to board of directors SemBioSys Genetics Inc. announces that Oye Olukotun, MD, MPH, FACC, FAHA, has agreed to join the board of directors of the company. Dr. Olukotun is the co-founder and chief medical officer of VIA Pharmacueticals, a company focused on cardiovascular disease treatments. He will replace Dr. Douglass Given, who is retiring from the board of SemBioSys after serving for seven years.
|
|
December 07 2007
Æterna Zentaris sells Echelon Biosciences to Frontier Scientific Æterna Zentaris Inc. has completed the sale of all issued and outstanding shares of its wholly-owned Salt Lake City, Utah based subsidiary, Echelon Biosciences Inc., to Frontier Scientific Inc. The transaction represents $3.2 million, including $2.6 million upfront and payable immediately with a $0.6 million in contingent consideration.
|
|
December 07 2007
Theratechnologies announces publication of its 26-week Phase III data Theratechnologies announces that the results from its first Phase III clinical trial, using tesamorelin (TH9507), have been published in the Dec. 6, 2007 New England Journal of Medicine.
|
|
December 07 2007
BC Advantage Funds surpasses $9.5 million in venture fund sales BC Advantage Funds (VCC) Ltd. announces that the Advantage Venture Fund (BCA100 on Fundserve) has surpassed $9,550,000 in sales. With less than $450,000 remaining, the fund is expected to sell out within the week.
|
|
December 04 2007
Industry Canada: Government delivers on Budget 2007 commitment to fund seven Centres of Excellence The Honourable Jim Prentice, Minister of Industry, and the Honourable Jim Flaherty, Minister of Finance, announce that $105 million will go towards funding seven new Centres of Excellence focused on priority areas in research and commercialization for Canada.
|
|
December 04 2007
Feds give $5M boost to biofuels sector A new ethanol plant will be built in Unity, Saskatchewan, as a result of the new federal ecoAgriculture Biofuels Capital (ecoABC) initiative.
|
|
December 04 2007
ProMetic reorganizes at management level to capitalize on corporate development opportunities ProMetic Life Sciences Inc. announces a reorganization at its management level in order to better position the company to capitalize on recent and upcoming corporate development activities related to ProMetic’s main value drivers.
|
|
December 04 2007
Viterra names new addition to senior management team SK-Viterra appoints Donald J. Chapman to its senior management team, as senior vice president of International Grain, based in Calgary.
|
|
December 04 2007
Protox appoints new chief scientific officer Protox Therapeutics Inc. announces the appointment of Dr. Samuel Denmeade to the position of chief scientific officer following Dr. Tom Buckley’s retirement from active laboratory research.
|
|
December 04 2007
Protiva grants Merck non-exclusive license to SNALP technology Protiva Biotherapeutics Inc. has granted Merck & Co., Inc. a non-exclusive license to Protiva’s SNALP (Stable Nucleic Acid-Lipid Particles) technology for ongoing research and development of therapeutics in the emerging field of RNA interference (RNAi).
|
|
December 04 2007
MaRS Landing welcomes Jessica Demeter The MaRS Landing team has appointed Jessica Demeter to the position of project coordinator.
|
|
December 04 2007
Transition Therapeutics receives remaining payment from Elan Corporation Transition Therapeutics Inc. announces the receipt of US$7.5 million, constituting the second half of a US$15 million upfront payment made under the company’s global collaboration agreement with a subsidiary of Elan Corporation for the Alzheimer’s disease drug candidate ELND-005/AZD-103.
|
|
December 04 2007
Miraculins announces new chief financial officer Miraculins Inc. announces that Eric Johnstone has been appointed as chief financial officer.
|
|
December 04 2007
Dealmakers Dalton Medicinal Chemistry Partners (Toronto, ON), the medicinal chemistry arm of Dalton Pharma Services, reaches an agreement with Boehringer Ingelheim (Canada) Ltd.
|
|
December 03 2007
Genzyme Corporation makes important investment in Prince Edward Island Genzyme Corporation announces the acquisition of Diagnostic Chemical Limited’s diagnostic division, considering it an important and positive step in the growth of P.E.I’s bioscience sector.
|
|
December 03 2007
Inflazyme Pharmaceuticals to commence trading on the NEX Exchange under the new ticker symbol IZP.H Inflazyme Pharmaceuticals announces that it will commence trading on the NEX Exchange under the new ticker symbol IZP.H, effectively ending its trade on the TSX.
|
|
December 03 2007
University Technologies International and BioAlberta create partnership to strengthen Calgary's bioindustry University Technologies International (UTI) and BioAlberta announce a partnership that focuses on creating stronger technology-based companies within the Calgary region and improving the technology commercialization process for early stage technologies.
|
|
December 03 2007
Aschaffenburg University chooses Stratophase to explore commercial applications of biodetection technology The first complete sensing unit based on Stratophase's patented biochemical detection technology has been selected by the University of Applied Sciences at Aschaffenburg for a three-year government funded research project.
|
|
December 03 2007
Oncolytics Biotech Inc. announces issuance of 24th U.S. patent Oncolytics Biotech Inc. announces that it has been granted U.S. patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
|
|
November 30 2007
Neuromed appoints Jeffrey Arcara and Gene Wright to senior management team Neuromed Pharmaceuticals announces that Jeffrey Arcara and Gene Wright have joined Neuromed as vice president of Business Development and vice president of Project Leadership, respectively. Both are newly created positions.
|
|
November 30 2007
New Chair for Canada’s Technology Triangle Inc Regional Economic Development Partnership to be led by John Doherty John S. Doherty is the new Chair of Canada's Technology Triangle Inc, the public-private regional economic development partnership marketing Waterloo Region and the cities of Cambridge, Kitchener and Waterloo to the world.
|
|
November 21 2007
Warnex to provide bioavailable testosterone testing to Organon Canada Warnex Inc. announces that its Medical Laboratories division has signed an agreement with Organon Canada Ltd., a renowned biopharmaceutical company based in Scarborough, ON, to provide bioavailable testosterone testing to its customers across Canada.
|
|
November 21 2007
Courtney Pratt to head Toronto Region Research Alliance The board of directors of the Toronto Region Research Alliance (TRRA) appoints Courtney Pratt chairman of the board of directors effective immediately. Pratt will assume the role of president and chief executive officer.
|
|
November 21 2007
Draxis Health selected by Johnson and Johnson consumer companies, Inc. for major contract manufacturing relationship Draxis Pharma, the contract manufacturing division of DRAXIS Health Inc., has expanded its existing contract manufacturing relationship with Johnson & Johnson Consumer Companies, Inc.
|
|
November 21 2007
Transition Therapeutics Inc. to commence trading on the NASDAQ Capital Market Transition Therapeutics Inc. common shares began trading on the NASDAQ Capital Market on Aug.20, 2007, under the symbol ‘TTHI’.
|
|
November 21 2007
Stella M. Thompson joins Resverlogix board of directors Resverlogix Corp. announces that Stella Thompson has joined the board of directors. On the subject of her appointment Stella Thompson said, “I am very pleased to be joining the Board of Resverlogix because of the exciting prospects and the high caliber talent that exists on Board and the management team.”
|
|
November 21 2007
Viterra posts net earnings of $96 million in its fourth quarter Viterra, the new operating name for Saskatchewan Wheat Pool Inc., announces its fourth quarter results reporting $96.0 million in net earnings.
|
|
November 21 2007
Fulcrum Regulatory Services opens office in Vancouver Fulcrum Pharma, the drug development and strategic outsourcing services company, is pleased to announce that it now has regulatory expertise based in a new office, located on the east side of Vancouver in British Columbia.
|
|
November 21 2007
Dealmakers Healthscreen Solutions Inc. (Toronto, ON) announces that it has appointed Genoa Management Limited of Toronto as its investor relations advisor and independent capital markets counsel.
|
|
November 16 2007
AIM Therapeutics completes private financing round to develop breakthrough medical treatments for asthma and inflammatory disorders AIM Therapeutics Inc. completes a $4 million private financing equity round to advance breakthrough medical treatments for asthma and inflammatory disorders.
|
|
November 16 2007
Mistral Pharma signs an in-licensing deal with Clinimed Mistral Pharma Inc. signs a licensing agreement with CliniMed, for the marketing and distribution of INSTILLAQUILL for the Canadian market.
|
|
November 16 2007
Stem Cell Therapeutics enters into a bought deal agreement for gross proceeds of $10.5 million Stem Cell Therapeutics enters into an agreement for gross proceeds of $10.5 million with a syndicate of underwriters led by Dundee Securities Corporation under which the underwriters have agreed to buy 30,000,000 units from SCT on a bought deal basis and sell them to the public at a price of $0.35 per unit.
|
|
November 15 2007
Biovail enters into development agreement Biovail Corporation enters into an agreement with Pharma Pass II for the early-stage development of BVF-068, a product for the treatment of a central nervous system disorder, and BVF-247, a novel formulation of a cardiovascular agent.
|
|
November 15 2007
BioRelix and Dalton Medicinal Chemistry sign research agreement BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.
|
|
November 02 2007
Lions Capital increases investment in Protox Therapeutics Lions Capital Corp. makes an additional investment in Protox Therapeutics on behalf of two of its funds under management- BC Advantage Funds Ltd. and the Pender NDI Life Sciences Fund Inc. doing business as the Advantage Life Science Fund II.
|
|
November 02 2007
MedBioGene engages U.S. consulting firm to drive partnering efforts MedBioGene Inc. announces that it has engaged JRG Ventures as its strategic business advisor. JRG advises high-growth companies in the areas of life sciences, healthcare services and systems and information technology.
|
|
November 01 2007
Pfizer investment in B.C. healthcare system marks new era of partnership Pfizer Canada announces a $4.25 million dollar investment in two B.C. research initiatives focused on HIV/AIDS and cardiovascular prevention. LifeSciences BC views the investment as a tremendous step forward in advancing towards a sustainable healthcare system in British Columbia.
|
|
November 01 2007
Sigma-Aldrich and the Universite de Montreal establish collaboration for RNA interference studies Sigma-Aldrich enters into a collaboration with the Institute of Research in Immunology and Cancer (IRIC) of the Universite de Montreal. This collaboration, made possible through grants from Genome Quebec and contributions by Sigma-Aldrich, will leverage Sigma's RNA Interference (RNAi) technologies for the purpose of identifying potential new drug targets.
|
|
October 23 2007
Neuromed raises US$53.3 million in Series E financing to accelerate development of pain treatments Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announces the completion of a Series E financing of US$53.3 million.
|
|
October 23 2007
Protox acquires research program from Medicenna Protox Therapeutics Inc. announces that it has entered into an asset purchase agreement with Medicenna Ventures Inc. for the acquisition of Medicenna's HUMxinTM program, a research program to develop fully humanized fusion proteins based upon the Bcl-2 family, which are key components of programmed cell death.
|
|
October 23 2007
CCR Technologies Ltd. reports new executive hires and promotion CCR Technologies Ltd., a leading chemical purification technology solutions and service provider, announces the hiring of four new executives and a new promotion.
|
|
October 23 2007
Dealmakers Ethica Clinical Research Inc. (Montreal, QC), a contract research organization (CRO) has formed a joint venture with the Hyderabad-based Matrix Group.
|
|
October 23 2007
Sonomax achieves important milestone: first million dollar quarter Sonomax Hearing Healthcare Inc. announces its results for the second quarter ended June 30.
|
|
October 23 2007
CV Technologies appoints new director CV Technologies Inc. announces that Maurice (Ted) Bilyea of Toronto has accepted an invitation to join its board of directors. Bilyea's appointment was effective Aug. 27.
|
|
October 19 2007
Isotechnika announces interim three month data from phase 2B kidney transplant Isotechnika Inc. announces its audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA247.
|
|
October 19 2007
Elastin Specialties Inc. forms partnership with Novozymes A/S of Denmark Toronto-based Elastin Specialties Inc. formalizes an agreement with Novozymes A/S of Denmark, one of the largest protein manufacturers in the world.
|
|
October 19 2007
ViRexx announces appointment of directors and interim chief executive officer and formation of special committee ViRexx Medical Corp. elects Peter P. Smetek, Jr., Michael P. Marcus, Yves Cohen, Douglas Gilpin and Jacques LaPointe to the board of directors.
|
|
October 19 2007
Stem Cell Therapeutics Corp. announces first quarter 2007 financial results Stem Cell Therapeutics Corp. announces its financial results for the period ended March 31, 2007.
|
|
October 19 2007
Transition Therapeutics announces third quarter fiscal 2007 financial results Transition Therapeutics Inc. announces its financial results for the quarter ended March 31, 2007.
|
|
October 05 2007
Medical Ventures announces change in executive management Medical Ventures Corp. announces Alexei Marko has taken the role of company president and chief operating officer, effective immediately. Paul Geyer will continue in his capacity as CEO and chair of the board of directors.
|
|
October 05 2007
Med BioGene appoints Dr. Melanie M. Mahtani as executive advisor, commercial development Med BioGene Inc. is pleased to announce the appointment of Melanie M. Mahtani, Ph.D. as executive advisor, commercial development.
|
|
October 05 2007
Healthscreen signs National Commercial Alliance agreement with ZoomMed Healthscreen Solutions Inc. and ZoomMed, the developer of the ZRx Prescriber, an electronic prescribing tool, jointly announce that they have signed a national distribution agreement.
|
|
October 05 2007
Xillix to move from TSX to NEX Xillix Technologies Corp. (previously TSX:XLX) announces that it has completed the amended and restated consolidated plan of compromise and arrangement of the company and its subsidiaries dated Sept. 7, 2007 (the "Plan").
|
|
October 05 2007
Chemokine Therapeutics files for a public offering of units Chemokine Therapeutics Corp. announces that it has filed a registration statement with the U.S. Securities and Exchange Commission and a preliminary short form prospectus with the Canadian securities regulators in connection with an offering of approximately US$25 million of units.
|
|
October 05 2007
BioMS Medical announces exercise of over-allotment option BioMS Medical Corp. announces that the underwriting syndicate led by Orion Securities Inc. and Desjardins Securities Inc. and Versant Partners Inc. have exercised its option to purchase an additional 2,100,000 units from treasury at a price of $2.75 per unit. Jefferies & Company, Inc. and Janney Montgomery Scott LLC are acting as U.S. placement agents in the offering on an exempt basis in the United States.
|
|
September 25 2007
Biovail responds to investor enquiries Biovail Corporation responded to various media and shareholder enquiries relating to the recent BVF-033 Non-Approval Letter from the U.S. Food and Drug Administration (FDA), which was disclosed by Biovail on July 20.
|
|
September 25 2007
Biovail provides update on BVF-033 Biovail Corporation has received a non-approval letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for BVF-033, a novel once-daily salt formulation of bupropion.
|
|
September 25 2007
ART and Stanford establish collaboration on treatment monitoring and diagnosis with SoftScan optical breast imaging ART Advanced Research Technologies Inc. enters into an agreement to develop and conduct clinical research with the Stanford Breast Imaging Section of Stanford University to evaluate the effectiveness of the SoftScan® optical breast imaging system in treatment monitoring and diagnosis of breast cancer.
|
|
September 25 2007
Dealmakers Building on a successful first phase of collaboration, Sonomax Hearing Healthcare Inc. (Montreal, QC) announces the execution of a commercial agreement with HearAtlast Inc. to become a key product supplier to the HearAtlast hearing stores.
|
|
September 25 2007
Forbes Medi-Tech on track for corporate objectives including revenue growth Canada Forbes Medi-Tech Inc. announces that its corporate objectives remain on track for year-over-year revenue growth while maintaining its commitment to change and improving Forbes' profile through M&A activity.
|
|
September 25 2007
TapImmune Inc. announces availability of new investor information TapImmune Inc. announces that it has launched a new corporate website with links to media features on its technologies.
|
|
September 21 2007
Tridural(TM) provides new option for the treatment of pain in Canada Paladin Labs Inc. (TSX:PLB) and Labopharm Inc. announces the Canadian launch of Tridural(TM) once-daily tramadol product. Tridural(TM) is a unique treatment option developed as a first-line therapy for adult patients with moderate pain who require treatment for several days or more that provides 24-hour pain relief from a single tablet taken once-daily.
|
|
September 21 2007
Zecotek closes non-brokered private placement for $2.5 million Zecotek Medical Systems Inc. announces that the company has closed its previously announced non-brokered private placement consisting of 1,563,000 Units at a price of $1.60 for gross proceeds of $2,500,800. The original $2,000,000 private placement announced on August 14, 2007, was oversubscribed and subsequently increased to $2,500,800 on closing.
|
|
September 21 2007
Meridian Co. proudly announces Roberta Flack as celebrity spokesperson for its Lapex 2000 Lipolaser (BCS) Meridian Co., Ltd. announces that Roberta Flack has been chosen to be its celebrity spokesperson for the LAPEX 2000 LipoLaser (BCS). This innovative medical device has recently received a CE Mark approval in the European Union and is currently pending a FDA 510 (K) clearance in the United States.
|
|
September 20 2007
MDS Capital Corp. announces investment team promotions and changes its name to Lumira Capital Corp. MDS Capital Corp., one of North American's oldest venture capital firms targeting health and life science investments, announces key management promotions and that it has changed its name to Lumira Capital Corp.
|
|
September 20 2007
Prollenium Medical Technologies announces partnership agreement with Ajanta Pharma to market Revanesse® in India Ajanta Pharma has entered into an in-licensing agreement with Prollenium Medical Technologies and will have exclusive marketing rights for Prollenium's highly successful dermal filler 'Revanesse(R)' in India.
|
|
September 19 2007
Pool announces $200 million senior note offering The Saskatchewan Wheat Pool Inc. (the "Pool") has filed a preliminary short form prospectus for the offering in Canada of C$200 million of senior notes (the "note").
|
|
September 14 2007
Biovail says settlement with Maris, BAS expected to be helpful in suit against hedge funds and others Biovail Corporation states that, contrary to implications in an article published by the New York Post today, it very much intends to proceed with its lawsuit against a group of hedge funds, analysts, investment and brokerage firms that Biovail alleged conspired to manipulate the market and drive down Biovail's share price to benefit its own stock positions.
|
|
September 07 2007
Canadian biotech SemBioSys enters skincare market with dedicated business unit The way in which many cosmetics and personal care items are developed is about to change, thanks to the creation of a newly formed, dedicated business unit from Canadian based biotechnology company SemBioSys, called Botaneco.
|
|
September 07 2007
Meridian signs US$3.5 million sales contract with Enterone Co. Meridian Co., Ltd. announces that it has signed a contract with Enterone Co., Ltd. for exclusive marketing and distribution of Meridian's Digital Pulse Analyzer (DPA) in Korea.
|
|
September 07 2007
CV Technologies files restated financial statements for fiscal 2006 and first quarter of fiscal 2007 CV Technologies Inc. releases restatements of its previously reported consolidated financial statements for the year ended Sept. 30, 2006 and interim consolidated financial statements for the three month period ended Dec. 31, 2006.
|
|
September 06 2007
ART and NRC Institute for Biological Sciences collaborate ART Advanced Research Technologies Inc. (ART) announces that a collaboration agreement has been signed with the National Research Council of Canada's Institute for Biological Sciences (NRC-IBS) for the development of client-oriented diagnostic applications using the company's proprietary time domain technology, in the emerging discipline of molecular imaging.
|
|
September 06 2007
ProMetic raises $6 million ProMetic Life Sciences Inc. announces that it has received share purchase offers from U.S. institutional investors and therefore will file two Supplements to a short form base shelf Prospectus of ProMetic that was previously filed on Nov. 3, 2006.
|
|
August 28 2007
Thermo Fisher Scientific acquires OptiCell product line Thermo Fisher Scientific Inc. announces it has acquired all assets of the OptiCell(TM) product line from BioCrystal Ltd. Included in the transaction are trademarks, production equipment, inventory, and 12 patents related to OptiCell technology.
|
|
August 24 2007
GeneNews secures $2 million for development of prostate biomarkers GeneNews Limited, a company focused on developing simple blood-based biomarker tests for the early detection of diseases and personalized health management, has come to an agreement with an Asian Biomedical consortium to develop blood-based biomarkers for the detection and management of prostate diseases.
|
|
August 24 2007
Warnex to market Ipsogen leukemia service Warnex Inc. announces it has signed an exclusive agreement with Ipsogen SAS, a molecular diagnostic company based in Marseille, France, to market Ipsogen's leukemia molecular diagnostic service in Canada.
|
|
August 17 2007
TOPIGEN secures Cdn$26M in Series C venture financing TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, announces the closing of C$26 million (US$25 million) in a Series C financing round.
|
|
August 17 2007
Cangene meets all regulatory and manufacturing requirements for 'usable product' on two U.S. government contracts Cangene Corporation reports that it has met all the regulatory and manufacturing requirements for the 'usable product' milestone on contracts with the U.S. government for products to treat botulism and inhalational anthrax.
|
|
August 15 2007
One of Canada's leading healthcare litigators joins Gowlings' Toronto office Scott Jolliffe, National Managing Partner of Gowling Lafleur Henderson LLP announces the arrival of Mary M. Thomson to the firm's Toronto office as a senior partner in the Advocacy Department.
|
|
August 15 2007
ViRexx makes change in management and board of directors ViRexx Medical Corp. announces that Dr. D. Lorne Tyrrell has resigned as chief executive officer, chief scientific officer and a director of ViRexx. Dr. Tyrrell will continue to serve as chief scientific advisor to ViRexx pursuant to a consulting agreement.
|
|
August 15 2007
Dealmakers MediSolution (Montreal, QC) releases its results for the fourth quarter and year ended March 31, 2007.
|
|
August 15 2007
BioNova elects three new board members The Nova Scotia Biotechnology and Life Sciences Industry Association elects three new member directors during its Annual General Meeting.
|
|
August 15 2007
Amorfix receives approval to list on the Toronto Stock Exchange Amorfix Life Sciences announces that the common shares of the company have been conditionally approved for listing on the Toronto Stock Exchange (TSX). Amorfix is currently listed on the TSX Venture Exchange.
|
|
August 15 2007
ARIUS appoints chief scientific officer ARIUS Research Inc. appoints Robert Gundel, Ph.D., MBA, to the position of chief scientific officer. Dr. Gundel brings to ARIUS more than 25 years of experience in the biotechnology and pharmaceutical industry.
|
|
August 15 2007
ProMetic and Laboratorios Dermatologicos Darier S.A. enter into agreement for PBI-1308 with respect to dermatological disorders BioSciences Inc., the drug development subsidiary of ProMetic Life Sciences Inc., and Laboratorios Dermatologicos Darier S.A., a leader in dermatology in Mexico, announced they have signed an agreement for ProMetic's synthetic anti-inflammatory compound PBI-1308 in dermatological disorders.
|
|
August 14 2007
ViRexx announces collaboration with the NINT and (DRDC Suffield) with networking and financial contribution ViRexx Medical Corp. announces that it has signed collaboration agreements with the National Research Council Canada's National Institute for Nanotechnology (NINT) and Defence Research and Development Canada Suffield (DRDC Suffield) with networking and financial contribution from NRC-IRAP.
|
|
August 14 2007
Biovail board of directors appoints Dr. Douglas Squires as interim chairman Biovail Corporation announces that the company's board of directors has appointed Biovail chief executive officer (CEO) and board member, Dr. Douglas Squires as interim chairman of the board.
|
|
August 14 2007
Co-discoverer of Lipitor(R) joins Resverlogix board of directors Resverlogix Corp. welcomes a new face to its board of directors as it appoints Roger Newton, PhD, effective July 10, 2007.
|
|
August 10 2007
Paladin and Glide Pharma sign exclusive agreement for novel needle-free drug delivery system Paladin Labs Inc. has entered into an exclusive license and distribution agreement with Glide Pharmaceutical Technologies Limited to develop and market Glide Pharma's innovative Glide SDI(TM) (solid dose injector) needle-free drug delivery products in Canada.
|
|
August 10 2007
Biovail enters into license and development agreement Biovail Corporation announces that a subsidiary, Biovail Laboratories International SRL, has entered into a license and development agreement with an undisclosed, privately held, drug-development company for the exclusive global rights to BVF-324, a novel product for the treatment of a prevalent sexual dysfunction.
|
|
August 09 2007
Paladin expands distribution agreement with Shire HGT to include ELAPRASE(TM) Paladin Labs Inc. has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies, Inc. Under the new agreement, Paladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL(R) (agalsidase alfa) for Fabry disease.
|
|
July 26 2007
Isotechnika partner receives no objection letter from Health Canada Isotechnika Inc. announces its partner, Lux Biosciences, has received a No Objection Letter from Health Canada to investigate ISA247 (referred to as LX211 by Lux) in Phase II/III clinical trials for the treatment of uveitis.
|
|
July 26 2007
Dealmakers Resverlogix Corp. (Calgary, AB) closes bought deal private placement providing for the sale and issuance of US$25 million in aggregate principal amount of secured convertible promissory notes.
|
|
July 26 2007
Maker of COLD-fX appoints chief operating officer CV Technologies Inc., the makers of the popular cold and flu remedy COLD-fX(R), appoints Ross Montagano as its new chief operating officer (COO).
|
|
July 26 2007
MediSolution undergoes facelift Leading healthcare and service sector IT company MediSolution has formally unveiled its new brand identity and renamed its MPlex Solutions public and service sector division to Virtuo Solutions effective immediately.
|
|
July 26 2007
MaRS Landing expands its team MaRS Landing announces the addition of Barbara Dillingham its project manager as well as the appointment of Michelle Schurter as the company's director of government and corporate affairs.
|
|
July 26 2007
Sigma-Aldrich acquires Molecular Medicine BioServices Sigma-Aldrich Corporation announces it has acquired Molecular Medicine BioServices Inc. (MMB), a biopharmaceutical contract manufacturing organization (CMO) to further enhance the biologics capabilities within its SAFC Pharma business segment.
|
|
July 26 2007
Vasogen closes previously announced financing Vasogen Inc. announces the closing of its previously announced financing for US$16 million in gross proceeds through the sale of its common shares at a price of US$3.25 under the terms of the purchase agreements.
|
|
July 26 2007
Joseph Beckman joins Amorfix Amorfix Life Sciences, a company focused on diagnostics and treatments for brain wasting diseases, announces the appointment of Dr. Joseph Beckman to its scientific advisory board.
|
|
July 26 2007
Amorfix achieves first milestone in therapeutic ALS partnership with Biogen Idec Amorfix Life Sciences receives notice from Biogen Idec that it will be exercising the first milestone investment under the August 2006 research and investment agreement. The milestone investment allows Biogen Idec to retain its exclusive worldwide option to license Amorfix's therapeutic candidates for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease.
|
|
July 26 2007
Amorfix commences trading on the Toronto Stock Exchange Amorfix Life Sciences announces that its common shares have been approved for listing on the Toronto Stock Exchange (TSX) and will no longer trade on the TSX Venture Exchange. Trading will be done under the symbol 'AMF'.
|
|
July 26 2007
Resverlogix closes US$25M bought deal Resverlogix Corp. closes a bought deal private placement on June 7, 2007, in the aggregate US$25 million of senior secured convertible promissory notes due June 6, 2012 and accompanying warrants to purchase, in the aggregate, 529,350 common shares of Resverlogix.
|
|
July 26 2007
Thallion closes sale of majority stake in Caprion Proteomics to Great Point Partners Thallion Pharmaceuticals Inc. closes the previously announced sale of an 80% stake in the company's wholly-owned proteomics business, Caprion Proteomics GP, to a company formed by Great Point Partners, LLC of Greenwich, CT. Thallion will retain a 20% equity interest in the newly created company, to be called Caprion Proteomics Inc., with the remaining 80% owned by Great Point Partners.
|
|
July 25 2007
Clinical Trials & Patents Liponex Inc. (Ottawa, ON) reports further analysis of its CRD5 Phase I/II clinical trial has shown its lead product to be safe in dyslipidemic patients.
|
|
July 13 2007
Pall teams up with RITT to advance transplantation science Pall Corporation announces the establishment of a collaborative sponsorship agreement with the Research in Immune Tolerance in Transplantation (RITT) program at the Toronto General Hospital (University Health Network) located in Toronto.
|
|
July 13 2007
Canadian, British and American scientists launch genome partnership An international team will use state-of-the-art, high-density microarrays and new computer algorithms to improve the detection of variants in the human genome, which are implicated in various diseases.
|
|
July 13 2007
Canadian Cardiovascular Society, mdBriefCase and AdvancingIn team up to provide online resources The Canadian Cardiovascular Society (CCS), AdvancingIn and mdBriefCase Inc. form a new partnership to provide on-line support for Canadian cardiovascular healthcare professionals. Advancing In Cardiovascular Health will provide CCS members and healthcare professionals with an interest in cardiovascular medicine with access to free, convenient, interactive continuing educational programming resources, including CME programs, eSymposia and national discussion forums.
|
|
July 13 2007
Med BioGene closes second and final tranche of private placement Med BioGene Inc. closes the second and final tranche of its previously announced private placement. MBI issued an aggregate of 677,500 units at a price of $0.45 per unit for aggregate gross proceeds of approximately $305,000.
|
|
July 13 2007
CV Technologies confirms trading to resume; updates new corporate priorities CV Technologies Inc. confirms that Securities Commissions in Alberta, Ontario and British Columbia have lifted their Cease Trade Orders, clearing the way for the Toronto Stock Exchange to lift the trading halt on CVQ stock.
|
|
July 13 2007
Warnex engages GMP Securities L.P. as advisor Warnex Inc. engages GMP Securities L.P., an institutional investment dealer with locations across Canada, to act as advisor in its previously announced review of strategic options.
|
|
July 10 2007
PerkinElmer and Axxam to deliver advanced screening solutions PerkinElmer, Inc. signs a worldwide licensing agreement with Axxam SpA, a Milan, Italy-based company focused on early-stage discovery research and services for the life science industry, to become the exclusive provider of Axxam's Photina(R) photoprotein technology to the drug discovery market.
|
|
July 10 2007
Kendle selects ClinPhone EDC as preferred solution ClinPhone signs an agreement to utilize ClinPhone EDC to standardize its method of capturing clinical data for its biopharmaceutical customers worldwide.
|
|
July 05 2007
GE Healthcare and Abbotsford Regional Hospital and Cancer Centre sign $30 million agreement GE Healthcare will provide more than $30 million in equipment and services to the Abbotsford Regional Hospital and Cancer Centre, scheduled to open for patients in summer 2008. GE Healthcare was uniquely positioned to help identify the various needs of the hospital and meet them with equipment that is among the most innovative and technologically advanced on the market.
|
|
July 03 2007
Warnex signs agreement with Clinique Radiologique Quatre-Bourgeois to offer Prenatest(R) screening in Quebec City Warnex Inc. announces that it has signed an agreement with Clinique radiologique Quatre-Bourgeois to provide the Prenatest(R) prenatal screening test in Quebec City.
|
|
July 03 2007
Abbott and Caprion extend partnership to discover antibody targets for cancer Abbott and Caprion Proteomics extend its discovery partnership to investigate viable human therapeutic antibody targets for oncology using its CellCarta(R) technology platform. The two companies began working together on lung cancer targets three years ago.
|
|
July 03 2007
Neurochem announces it has obtained written consent from its shareholders Neurochem Inc. announces that, in connection with its previously announced private placement of US$80 million aggregate principal amount of convertible notes and warrants to purchase common shares, it has provided the Toronto Stock Exchange with written evidence that holders of more than 50% of its securities are familiar with the terms of the Notes and Warrants and are in favour thereof.
|
|
June 25 2007
Stem Cell Therapeutics Corp. announces financial results Stem Cell Therapeutics Corp. (SCT) announces its financial results for the period ended Dec. 31, 2006.
|
|
June 25 2007
NeuroScience Canada appoints directors Allan R. Taylor, interim chair of the board of directors of NeuroScience Canada announces the appointments of three directors.
|
|
June 25 2007
Dealmakers Saskatchewan Wheat Pool Inc. (Regina, SK) announces that the $275,400,000 subscription receipt offering has closed successfully and that Genuity Capital Markets, TD Securities Inc. and National Bank Financial Inc., that acted as underwriters in connection with the offering, have exercised its over-allotment option in full to purchase an additional 5,100,000 subscription receipts at the offering price of $8.10 per subscription receipt, bringing aggregate proceeds of the offering to $316,710,000.
|
|
June 25 2007
Protox reports 2006 achievements and financial results Protox(TM) Therapeutics Inc. announces its year-end financial statements for the 12 months ending Dec. 31, 2006, revealing not only its financial status but its achievements during the year.
|
|
June 25 2007
Pfizer Canada receives IAPA Health and Safety award IAPA (Industrial Accident Prevention Association) recognizes the workplace health and safety accomplishments of Pfizer Canada's Arnprior facility with a Level I Health & Safety Achievement Award.
|
|
June 25 2007
ARIUS makes changes to board of directors Arius Research Inc. announces that Joseph Zakrzewski has been appointed to the company's board of directors.
|
|
June 25 2007
Biophage Pharma appoints new chief financial officer Biophage Pharma Inc. announces the appointment of Louis Guindon as chief financial officer and treasurer of the corporation.
|
|
June 22 2007
BD Biosciences and StemCell Technologies sign license agreements with WARF BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc., a Vancouver-based life sciences company, announce they have entered into a worldwide license agreement with the Wisconsin Alumni Research Foundation (WARF).
|
|
June 18 2007
Health Canada allows Isotechnika to continue patients on ISA247 until commercialization Isotechnika announces that the company has received a No Objection Letter from Health Canada for the long term use of ISA247 in patients currently participating in the Canadian arm of the company's Phase 2b kidney transplant trial.
|
|
June 18 2007
Nuvo continues discussions with the FDA related to Pennsaid Nuvo Research Inc. is continuing discussions with the U.S. Food and Drug Administration to clarify and resolve matters raised by the FDA in its approvable letter for Pennsaid issued in December 2006. The discussions primarily concern the FDA's requirements for data to evidence the dermal safety of Pennsaid and its constituent components.
|
|
June 18 2007
GangaGen, University of Nottingham sign research agreement GangaGen Life Sciences Inc. and the University of Nottingham are engaging in a major research project to develop a bacteriophage-based treatment for the control of Campylobacter bacteria in poultry. Along with Salmonella, Campylobacter is the most common form of food-borne illness, infecting millions of people worldwide every year.
|
|
June 06 2007
Lawson Health Research Institute Announces Appointment Lawson Health Research Institute (London, ON) announces that it has appointed Dr. David Hill to the position of scientific director for the Institute.
|
|
June 06 2007
Neptune Technologies and Bioressources announce recent appointment Neptune Technologies and Bioressources announce that Thierry Houillon, recently appointed member of Neptune's board of directors and previous CEO of Danone Canada, has joined Neptune as the vice president, Business Development, Functional Food.
|
|
June 06 2007
Universal Measurement Solutions Ltd. has New VP of sales and marketing Universal Measurement Solutions Ltd. leverages its rapidly growing market presence with the addition of R.A. (Bob) Ell as VP of sales and marketing.
|
|
June 06 2007
Cipher announces new CFO appointment Cipher Pharmaceuticals Inc. announces that Norman C. Evans, CA, has been appointed chief financial officer of the company, effective immediately.
|
|
June 06 2007
Cytochroma Inc. announces new appointment Cytochroma Inc. announces the appointment of Dr. P. Martin Petkovich as full-time chief scientific officer.
|
|
June 06 2007
Aegera Therapeutics Inc. announces appointments Aegera Therapeutics Inc. announces the appointment of James M. Rae as chairman of the board and Trudie Resch as board director.
|
|
June 04 2007
AEterna terminates its license agreement with Solvay Pharmaceuticals Quebec biotech company AEterna Zentaris has regained exclusive worldwide rights for its lead Luteinizing Hormone-Releasing Hormone (LHRH) antagonist, Cetrorelix, after terminating its License and Cooperation Agreement in all remaining indications, including endometriosis, with its partner Solvay Pharmaceuticals.
|
|
June 04 2007
Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner Beckman Coulter, a manufacturer and distributor of biomedical testing instrument systems and research products, has chosen SAFC Supply Solutions business segment as a licensing partner for its fast deprotection chemistry technology.
|
|
June 04 2007
Allon Therapeutics closes $15 million bought financing deal Allon Therapeutics Inc. announces it has entered into a bought deal financing agreement with a syndicate of Canadian securities dealers under which the syndicate has agreed to purchase 12,500,000 units at a price of $1.20 per Unit, resulting in gross proceeds of $15 million.
|
|
June 04 2007
Advitech closes private placement deal with AgeChem Advitech Inc. announces the closing of a $970,000 private placement with AgeChem Venture Fund L.P. and new payment terms of its convertible debentures issued in 2004.
|
|
June 01 2007
New partnership leverages promising Canadian stem cell IP MaRS Discovery District and the Canadian Stem Cell Network (SCN) announce a partnership agreement whereby MaRS and SCN will work together to pursue long-term public or private financing for the translational development activities currently being undertaken by Aggregate Therapeutics Inc.
|
|
June 01 2007
ART Advanced Research Technologies Inc. closes a first portion of private placement ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that it has closed a first portion of approximately $4.5 million of its previously announced private placement of a total of approximately $5.5 million.
|
|
June 01 2007
Thermo Fisher Scientific appoints new director to Canadian team Murray Wigmore has been promoted to the director, Canada Commercial Sales and North America Consumables for the Scientific Instruments Division of the Advanced Products Group for Thermo Fisher Scientific.
|
|
May 24 2007
Ambrilia announces closing of $5.8 million private placement Ambrilia Biopharma Inc., a biopharmaceutical company specializing in the development of novel small molecules and peptides to treat infectious diseases and cancer, announces the closing of a $5.8 million private place.
|
|
May 22 2007
CCR Technologies Ltd. completes private placement CCR Technologies Ltd. announces that on April 16, 2007 the corporation completed a private placement of a series of secured convertible debentures in the aggregate principal amount of $500,000, which mature on Dec. 19, 2009.
|
|
May 17 2007
York University and Japanese biomedical foundation confirm partnership York University and Japan's Foundation for Biomedical Research and Innovation have formalized a memorandum of understanding to promote the development and commercialization of innovative medical devices used to diagnose, treat and even prevent illnesses.
|
|
May 16 2007
Cytochroma's new chief scientific officer to propel development and commercialization Cytochroma Inc. announces the appointment of Dr. P. Martin Petkovich as full-time chief scientific officer
|
|
May 16 2007
Performance Plants Inc. hires on new director of finance Performance Plants Inc., a Canadian agricultural biotechnology company, is pleased to announce the appointment of Drew Phillips CA as director of finance.
|
|
May 16 2007
Isotechnika Inc. completes bought deal financing Isotechnika Inc. completed a bought deal financing. The syndicate of underwriters led by GMP Securities, L.P. and including Canaccord Capital Corpoation, RBC Dominion Securities Inc. and National Bank Financial Inc. (collectively the Underwriters) purchased a total of 21,850,000 units at a price of $1.85 per Unit for gross proceeds of $40,422,500.
|
|
May 16 2007
Sonomax Hearing Healthcare Inc. brings in new COO Sonomax Hearing Healthcare Inc. announces that it has engaged Dennis Jewitt as its chief operating officer effective immediately.
|
|
May 16 2007
Natural Resources Canada Announces Government Funding Natural Resources Canada - Joe Preston, Member of Parliament for Elgin-Middlesex-London, on behalf of the Honourable Gary Lunn, Minister of Natural Resources, announces that the government will provide funding of $40,000 over two years for a pilot project to incorporate renewable energy in new homes.
|
|
May 16 2007
Neuromed Pharmaceuticals receives $2 million Neuromed Pharmaceuticals, a biopharmaceutical company developing chronic pain drugs, announces that it has received a milestone payment of $2 million.
|
|
May 16 2007
Variation Biotechnologies Inc. Announces Secured Financing Variation Biotechnologies Inc. (VBI), a privately held biopharmaceutical company focused on the development of vaccines for infectious diseases, announces it has secured US$35.7 million in Series A financing.
|
|
May 16 2007
Perspective Commercialization of genomics One of the great expectations of genomics in the 1990s was that it would radically and directly improve the business of drug discovery.
|
|
May 14 2007
Research partnership leads world in determining 3-D structure of proteins The Structural Genomics Consortium (SGC), an international research effort set up in 2004 to determine the three-dimensional structures of proteins relevant to human disease, posted its 375th protein structure in the public domain.
|
|
May 07 2007
PharmaGap announces $550,000 investment by Dundee Securities Corporation PharmaGap Inc. announces the purchase by Dundee Securities Corporation of 2,000,000 common equity units and 2,400,000 Series I Preferred Shares, for a total investment by Dundee of $550,000.
|
|
May 07 2007
Mazak Corporation Canada opens its Canada Headquarters A new Headquarters and Canadian Technology Centre is now open. Canada's Technology Triangle Inc. welcomes Mazak Corporation, a prestigious firm that is the North American manufacturing, sales and support arm of the leading international machine tool builder, Yamazaki Mazak Corporation of Oguchi, Japan.
|
|
May 04 2007
Medical Ventures Corp. builds board and management team Medical Ventures Corp. appoints Gene Starr to its board of directors as well as hiring Chris Clark, CA, as the director of finance.
|
|
April 25 2007
Neuromed licenses Phase 3 chronic pain product from ALZA Corporation Neuromed Pharmaceuticals Ltd. announces that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.
|
|
April 23 2007
Ocean Nutrition and Alicorp announce joint venture Ocean Nutrition Canada Limited (ONC), supplier of MEG-3(R) brand Omega-3 EPA/DHA functional food and dietary supplement ingredients, announces that it has signed a joint venture collaboration agreement with Alicorp S.A.A, Peru's leading edible oils and food manufacturer.
|
|
April 23 2007
CCR Technologies Ltd. completes private placement CCR Technologies Ltd. announces that it has completed a private placement of a series of secured convertible debentures (the 'Debentures') in the aggregate principal amount of $500,000 which mature on December 15, 2009 (the 'Private Placement').
|
|
April 18 2007
Amorfix appoints new board member Amorfix Life Sciences Ltd., a company dealing with the prevention, diagnosis and treatment of brain-wasting diseases, has appointed Michael Sonnenreich to its board of directors in the first of a series of moves and appointments that included the formation of a Scientific Advisory Board (SAB) to be chaired by Dr. Neil Cashman, chief scientific officer for Amorfix.
|
|
April 18 2007
Variation Biotechnology Inc. closes venture capital deal Variation Biotechnology Inc., a vaccine development company, announces that they closed a venture capital deal totalling Cdn$41.6 million.
|
|
April 18 2007
Labtronics Inc. announces new partnership with Symbion Systems Labtronics Inc., an industry leader in laboratory data integration and management solutions, announces a new partnership with Symbion Systems.
|
|
April 18 2007
Alberta Research Council enters agreement with Sage Biosciences Inc. In keeping with its mandate to help Alberta companies grow and prosper the Alberta Research Council (ARC)recently entered into a five-year collaborative research agreement with Sage Biosciences Inc.
|
|
April 18 2007
Cytochroma Inc. secures new funding Cytochroma Inc. announces that it has secured Cdn$21 million in new funding for the advancement of product development programs targeting vitamin D deficiency and related diseases inn chronic kidney disease (CKD).
|
|
April 18 2007
Neuragen goes national Popular Canadian drug store chain Shoppers Drug Mart has launched Origin BioMed Inc. into national status, with its decision to carry Origin's lead product Neuragen coast to coast, in all 1,046 Shoppers Drug Mart Stores.
|
|
April 18 2007
Bill Gates Tackles Biotechnology By Paul Crookall
Over the past two decades Bill Gates has quickly become the richest man in the world, while heading the leading company in the information and communications technology industry that is transforming the global economy. |
|
April 17 2007
Replenishing of plasma gelsolin can avert disease progression in critical care QSV Biologics, Ltd (QSV) and Critical Biologics Corp., announce the signing of a contract for cGMP manufacturing of resombinant human plasma gelsolin (rhu-pGSN), targeted for the prevention of life-threatening critical care complications associated with low plasma gelsolin levels.
|
|
April 17 2007
New VP research for TRLabs TRLabs has appointed Dr. Rainer Iraschko as its new VP Research out of its Calgary office.
|
|
April 17 2007
Ciphergen chooses mosaic to develop broad reimbursement strategy Ciphergen Biosystems, Inc. is teaming up with Mosaic Health Care Consultants, a heath care consulting firm, to further develop reimbursement strategies and programs for its ovarian tumor triage test.
|
|
April 12 2007
Warnex to perform pharmacogenetic and bioanalytical services for Novartis Canada's Gleevec(R) monitoring program Warnex Inc. will perform pharmacogenetic and bioanalytical services for Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field.
|
|
April 05 2007
Advitech announces the closing of an $885,000 private placement and a new stock option grant Advitech Inc. announces that it has completed a private placement by way of offering memorandum, announced on Feb. 28, 2007, for a total amount of $884,128. Of this amount, $448,000 comes from the issuance of convertible debentures and $436,128 from the issuance of units.
|
|
April 04 2007
Biophage signs milestone contract with Alberta Agriculture and Food Biophage Pharma Inc. reports that it has signed a groundbreaking contract with Alberta Agriculture and Food to conduct a pilot study for the large-scale production and purification of bacteriophage preparations in a biofermentor.
|
|
March 30 2007
Med BioGene announces private placement Med BioGene Inc. announces that it has entered into an agreement with Fraser Mackenzie Limited to act as exclusive lead agent in connection with a private placement of $4 million of units.
|
|
March 23 2007
Med BioGene signs research collaboration and option agreement Med BioGene Inc. announces a research collaboration and option agreement with Duke University to further develop and validate its genetic biomarkers for lymphoma and leukemia using its Gene Expression Profiling System.
|
|
March 23 2007
Transition Therapeutics Inc. builds on its CNS franchise with the acquisition of NeuroMedix Inc. Transition Therapeutics Inc. announces that it has signed an agreement to offer to purchase all of the outstanding shares of NeuroMedix Inc., a central nervous system ('CNS') focused biopharmaceutical company.
|
|
March 23 2007
Neuromed receives milestone payment of $2 million Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, announces that it has received a milestone payment of $2 million under its collaboration and license agreement with Merck & Co., Inc.
|
|
March 23 2007
Fusion Antibodies signs antibody engineering deal with ARIUS to develop new cancer antibodies Fusion Antibodies, a therapeutic antibody company focused on novel target identification for Oncology and Angiogenesis, has entered into a antibody engineering deal with ARIUS Research Inc., a leading Canadian biotech company, dedicated to personalizing cancer therapy.
|
|
March 12 2007
Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. to amalgamate Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. have come to an agreement that will see the two companies amalgamate into one.
|
|
March 12 2007
Genizon BioSciences announces agreement with Pfizer Inc. Genizon BioSciences announces a license and collaboration agreement with Pfizer Inc.
|
|
March 12 2007
QSV Biologics Ltd. and Artielle ImmunoTherapeutics Inc. Reach Agreement QSV Biologics Ltd. and Artielle ImmunoTherapeutics Inc. reached an agreement that will see the Canadian biologics manufacturer (QSV) undergo the process development and cGMP manufacturing of Artiele's Recombinant T cell receptor Ligand, the RTL 1000.
|
|
March 12 2007
Allon Therapeutics Inc. Receives Funding Canadian biotechnology company Allon Therapeutics Inc. announces it has obtained funding from The Michael J. Fox Foundation for Parkinson's Research.
|
|
March 12 2007
Victhom Human Bionics Inc. Receives Approval Victhom Human Bionics Inc. announces that it received approval from the Ethics Review Board of the rehabilitation centre where its clinical trial on gait disorders will be held.
|
|
March 12 2007
RapidLabs Signs Consultancy Agreement RapidLabs announces the signing of a consultancy agreement with Dr. Patricia Béretta. Dr. Béretta will augment the existing teams clinical knowledge and will assist in the formation of clinical strategies surrounding RapidLabs' novel approach to microbial identification and susceptibility testing.
|
|
March 09 2007
KGK expands KGK Synergize Inc. announces the completion of its amalgamation and expansion of its corporate head office and clinic in London, ON.
|
|
March 09 2007
CIRION appoints new vice president, Business Development To further enhance the growth of the CIRION operations, Dr. Sylvain Desrochers, PhD, president and CEO, announces the nomination of Fraser R. Day to the position of vice-president, Business Development.
|
|
March 09 2007
Government invests $5.4 million in green technology OFCRIN, a partnership between researchers from eight universities and 12 industry partners, has been awarded $5.4 million to develop new materials and manufacturing methods for fuel cells - a clean energy technology that can produce electrical power from a wide range of fuel sources.
|
|
March 09 2007
Alberta attracts international biodiesel investment BioAlberta and The Southern Alberta Alternative Energy Partnership are pleased to welcome BioKing - a biodiesel equipment manufacturer to Lethbridge.
|
|
March 02 2007
HIMSS Analytics expands footprint into Canada HIMSS Analytics announces plans to extend products and service offerings to the Canadian healthcare IT market.
|
|
March 02 2007
Medicago Inc. retains leading investor relations firm Medicago Inc., a developer of innovative protein manufacturing solutions using plants, announces that it has retained The Equicom Group Inc. to provide the company with strategic investor relations and financial communications services.
|
|
March 02 2007
The Jenex Corporation grants worldwide license to distribute and sell Therapik device The Jenex Corporation announces that it has signed a worldwide license agreement with Connecticut based Competitive Technologies to distribute and sell the corporation's patented Therapik thermal-therapy device, worldwide.
|
|
February 23 2007
For those planning to submit an ABIP network proposal - BIOCAP offers support For those people looking to submit an ABIP network proposal, BIOCAP offers support for applicants.
|
|
February 22 2007
Early stage venture capital firm Ventures West appoints new venture partner Ventures West announces that Kenneth Galbraith has joined the firm as venture partner. Galbraith is a well-known and an active member of the North American life sciences community with 19 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors.
|
|
February 12 2007
Alberta Research Council and Sage Biosciences sign collaborative research agreement In keeping with its mandate to help Alberta companies grow and prosper the Alberta Research Council (ARC) enters into a five-year collaborative research agreement with Sage Biosciences Inc that will bring new products in animal health and nutrition to the marketplace.
|
|
February 01 2007
Xenon to collaborate with Roche Xenon Pharmaceuticals has partnered with Swiss-based Roche to develop protein therapeutics targeting hemojuvelin (HJV) for the treatment of anemia of inflammation.
|
|
February 01 2007
ProMetic secures loan to improve financial shape To shed a weight on its share price, ProMetic Life Sciences Inc. secured a non-convertible $11.6 million loan from a US-based financial institution.
|
|
February 01 2007
Protox Therapeutics Inc. closes private placement Protox Therapeutics Inc. closed a second tranche of a previously announced private placement in December, raising an additional $875,000 on the placement of 1,750,000 units with new institutional and retail investors.
|
|
February 01 2007
Pacgen Biopharmaceuticals raises millions Pacgen Biopharmaceuticals Corp. raised over $7 million following an initial closing of 6,788,786 units.
|
|
February 01 2007
Supelco signs agreement with Lund Supelco, a division of Sigma- Aldrich has signed a distribution agreement with Lund, Sweden-based MIP Technologies AB to distribute its analytical and preparative Molecularly Imprinted Polymer (MIP) separation products.
|
|
February 01 2007
Millipore Corp. will develop serum free media Millipore Corp. will develop and market Edinburgh, U.K.-based Stem Cell Sciences' serum free media for the growth of human embryonic stem cells (hESCs).
|
|
February 01 2007
Ambit Biosciences collaborates with Cephalon Inc. Ambit Biosciences will collaborate with Cephalon Inc. to bring forward kinase inhibitors as candidates for clinical research.
|
|
January 15 2007
One of Canada's top 10 life science companies closes Ottawa areas largest life science VC deal of 2006 Variation Biotechnology Inc. (VBI)an innovative vaccine development company, and a 2006 Canadas Top 10 Life Science Company Competition Winnerannounces that it closed a venture capital deal Dec. 28, 2006 totaling Cad$41.6 million. Led by US-based Clarus Ventures, the financing included the participation of ARCH Venture Partners and 5AM Ventures as well as existing seed investors.
|
|
January 11 2007
CHDI Inc. To Provide Research Suport To MethylGene Inc. And EnVivo Pharmaceuticals CHDI Inc. has agreed to provide financial and preclinical research support to MethylGene Inc. and its American collaborator EnVivo Pharmaceuticals.
|
|
January 11 2007
Methanex Corp. And XinAo Group Strike Deal Methanex Corp. and China's XinAo Group have struck a long-term deal that will see Methanex supply an initial quantity of approximately 300,000 tonnes per annum of methanol to XinAo, beginning in late 2007.
|
|
January 11 2007
ProMetic BioSciences Ltd. Will Provide Adsorbent To Octapharma AG ProMetic BioSciences Ltd, the UK subsidiary of Montreal, QC-based ProMetic Life Sciences Inc. will provide Octapharma AG with scale-up quantities of a Mimetic LigandTM affinity adsorbent.
|
|
January 11 2007
Medical Ventures Corp. Consolidates Two Subsidiary Units, Angiometrx Inc. and PM Devices Inc. Medical Ventures Corp. has consolidated two subsidiary units, Angiometrx Inc. and PM Devices Inc.
|
|
January 11 2007
Forbes Medi-Tech Strikes Deal With Tesco Stores Ltd. Forbes Medi-Tech has struck a deal that will see Tesco Stores Ltd., the U.K.'s largest retailer, carry a strawberry flavoured yogurt drink incorporating Forbes' cholesterol-lowering ingredient ReducolTM.
|
|
January 10 2007
KGK closes private placement KGK Synergize Inc. has closed a private placement of common equity capital. Terms of the placement were not disclosed.
|
|
January 10 2007
Industry pundit joins Amorfix board Dr. Hans Black has been appointed to the board of directors of Toronto, ON-based Amorfix Life Sciences.
|
|
January 09 2007
Nuvo licenses Canadian Pennsaid Plus rights to subsidiary of Paladin Nuvo Research Inc. announces that Squire Pharmaceuticals Inc., a subsidiary of Paladin Labs Inc., has exercised its right to enter into a license with Nuvo to market and sell Pennsaid(R) Plus in Canada.
|
|
November 28 2006
Sonomax Hearing Healthcare Inc. Signs Renewal Agreement Sonomax Hearing Healthcare Inc. has signed a five-year renewal agreement with Alpine Hearing Protection in Germany valued at over $5 million.
|
|
November 28 2006
Adherex Technologies Inc. Partners With Liver Tumour Group Adherex Technologies Inc. will partner with the International Childhood Liver Tumour Strategy Group, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology (SIOP), for a Phase III trial of sodium thiosulfate, a drug developed by Adherex to reduce or prevent hearing loss in children associated with platinum-based chemotherapies. The trial will begin in early 2007.
|
|
November 28 2006
Forbes Medi-Tech Inc. Acquires TheraPei Pharmaceuticals Inc. Forbes Medi-Tech Inc. has acquired TheraPei Pharmaceuticals Inc. of San Diego, California, a privately held company formed with technology 'spun-out' of Sequenom Inc. Forbes issued a total of 94,672 common shares and paid approximately $400,000 US on closing.
|
|
November 28 2006
Xillix Technologies Corp. Obtains Protection From Creditors Xillix Technologies Corp. has sought and obtained an order of the British Columbia Supreme Court granting it protection from creditors.
|
|
November 28 2006
CCR Technologies Ltd. Acknowledges Statement Of Claim Filed CCR Technologies Ltd. acknowledged in October that a customer had filed a statement of claim against it in the Court of Queen's Bench of Alberta.
|
|
November 28 2006
Covalon Technologies Ltd. Acquires Gene Therapy Technology Covalon Technologies Ltd. has acquired Montreal based Perfusion Therapeutics' gene therapy technology.
|
|
November 27 2006
Feds fund search for alternatives to livestock antibiotics The University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) has received $1.75 million in new funding to support development of alternatives to antibiotics.
|
|
November 27 2006
Sonomax completes $1.25 million private placement Sonomax Hearing Healthcare Inc. announces that it has completed a private placement by issuing 5,000,000 units to Le Fonds d'investissement Actions-Croissance PME Inc. at a price of $0.25 per unit, for gross proceeds to Sonomax of $1,250,000.
|
|
November 21 2006
Canada, Quebec and private sector partners invest $100 million in business creation in the technology sector GO Capital Fund, managed by BDC, meets a market need to provide seed financing for Quebec firms.
|
|
November 13 2006
Orbus signs exclusive license, supply and distribution agreement for the Canadian market Orbus Pharma Inc. (TSX:ORB) (Orbus) announces that it has entered into an exclusive license, supply and distribution agreement with Gennium Pharma Inc. (Gennium) of Mississauga, ON, to supply a generic cephalosporin to the Canadian market.
|
|
November 07 2006
John Wiley & Sons Inc. and the International Society for Stem Cell Research sign agreement Publisher John Wiley & Sons Inc. and the International Society for Stem Cell Research have signed a multi-year agreement.
|
|
November 07 2006
VWR to expand Stratagene in Canadian market VWR International Inc. has assumed Canadian distribution for Stratagene Corp.
|
|
November 06 2006
Sonomax Hearing Healthcare Inc. Acquires VitaSound Audio Inc. Sonomax Hearing Healthcare Inc. acquired VitaSound Audio Inc. a hearing-aid manufacturer of record to Health Canada.
|
|
November 02 2006
Protiva to develop Ebola treatment The United States Defense Threat Reduction Agency has awarded a $3.6 million US grant.
|
|
November 02 2006
Canadian team joins "knock out" competition Dr. Geoff Hicks, director of the Manitoba Institute of Cell Biology will co-lead a team in the Canadian component of the International Knockout Mouse Project.
|
|
November 02 2006
Ambrilia Signs Distribution Deal With Merck Ambrilia Biopharma Inc. has granted Merck & Co. Inc. (Whitehouse Station, NJ) exclusive worldwide rights to its HIV/AIDS protease inhibitor (PI) program.
|
|
November 02 2006
Axela Biosensors Inc. Signs Agreement With Abnova Corp. Axela Biosensors Inc. signed a collaborative agreement with Abnova Corp. (Taipei City, Taiwan) to co-develop reagents and biomarker panels for use on Axela's dotLab System.
|
|
October 17 2006
Montreal firm licenses HIV/AIDS treatment to Merck Merck & Co. is paying US$17 million to Abrilia Biopharma Inc. for the rights to PPL-100, an protease inhibitor that has completed a Phase I single-dose pharmacokinetic study
|
|
October 03 2006
Ambrilia Biopharma Receives Milestone Payment As part of a licensing deal with an undisclosed U.S. partner, Ambrilia Biopharma Inc. has received a milestone payment for its late-stage oncology specialty generic Octreotide, designed for the treatment of acromegaly and certain rare digestive system cancers.
|
|
October 03 2006
Human BioSystems Signs Agreement With Utek Corp. Palo Alto, Calif.-based Human BioSystems (HBS) has signed an agreement with Utek Corp. (Tampa, FL) that is designed to assist HBS to identify and evaluate potential business partners.
|
|
October 03 2006
Covalon Sues Former CEO Covalon Technologies Ltd. has initiated proceedings against its former chairman and CEO, John Robert Allan, his spouse and Durimport Marine Ltd., a company owned and controlled by both.
|
|
October 03 2006
Biovail Seeks Delay of Generic Antidepressant, Sues FDA Biovail Corp. has filed suit against the U.S. Food and Drug Administration (FDA) in an effort to have a hand in how the FDA determines bioequivalency for a generic form of the antidepressant Wellbutrin® XL.
|
|
October 02 2006
Ottawa Life Sciences Council presents annual awards The Ottawa Life Sciences Council (OLSC) presented its 2006 Ottawa Life Sciences Achievement Awards this week to recognize individuals who have made significant contributions to Ottawa's emerging life sciences sector. This year's recipients are Dr Annette O'Connor (Health Innovation Award), Liponex Inc (Company of the Year Award), Dr Rees Kassen (Promising Scientist Award), and Dr W. Bruce Jackson (Career Achievement Award).
|
|
October 02 2006
Wex Seeks Asian Investment Wex Pharmaceuticals Inc. is offering Chinese investors a private placement of 7,773,584 common shares at a price of $0.265 per share.
|
|
October 02 2006
ProMetic and Nabi Sign Agreements ProMetic Life Sciences Inc. has signed licensing and associated services and supply agreements with Nabi Biopharmaceuticals that will use ProMetic's Mimetic Ligands technology to manufacture selected plasma-derived hyperimmune products.
|
|
October 02 2006
Warnex Inc. Partners With Eppendorf Warnex Inc. has partnered with Eppendorf to combine Eppendorf's Mastercycler® ep realplex real-time PCR system with Warnex's pathogen detection kids and software for food safety testing.
|
|
September 13 2006
Perkins Lands University Collaboration Agreements PerkinElmer Inc. has signed two multi-year research collaboration agreements with Johns Hopkins University and the University of Birmingham to establish the groundwork for developing technologies for the discovery of biomarkers leading to diagnostics and personalized medicine.
|
|
September 13 2006
Waters Collaborates on Chinese Food and Environmental Safety Waters Corp. will collaborate with the China Municipal Center for Disease Prevention and Control, Beijing Municipal Center for Disease Prevention and Control and the Research Center for Eco-Environmental Sciences of the Chinese Academy of Sciences to provide technology and expertise for food safety analysis and environmental regulatory compliance.
|
|
September 13 2006
Space Agency Continues Support for Osteoporosis Lab The Canadian Space Agency has granted Millenium Biologix Corp. a continuation of contract for an automated osteoporosis mini lab for space missions using the company's SkeliteTM scaffold and substrate technology.
|
|
September 13 2006
Wyvern Scientific Signs Distribution Deal Cambridge, Ont.-based Wyvern Scientific Inc. has signed a distribution deal with Selective Micro Technologies that will provide Canadian companies with access to a technology that aids in the control of bioslime, algae and bacteria.
|
|
September 13 2006
Labtronics Links With Agilent Labtronics Inc. and Agilent Technologies Inc. have signed a distribution agreement authorizing Agilent to distribute Labtronics' LimsLink and LimsLink CDS integration solutions to its customers.
|
|
September 13 2006
Millipore, Serologicals Merge Millipore Corp. has completed the acquisition of Serologicals Corp.
|
|
September 11 2006
Partners Collatorate To Co-Develop Series Of RNA Antogonists Enzon Pharmaceuticals Inc. and Santaris Pharma will collaborate to co-develop and commercialize a series of RNA antagonists.
|
|
September 11 2006
Agreement Signed To Sell Contour Threads Product Line In Japan Vancouver-based Angiotech Pharmaceuticals Inc. has signed an agreement with KMT Japan to sell its Contour ThreadsTM product line in Japan.
|
|
September 11 2006
New Training Program In Taipei PharmEng International Inc. has begun a training program in Taipei, Taiwan.
|
|
September 11 2006
Agreement Signed To Commercialize RVP Tm Bioscience Corp. has signed a distribution agreement with Ramcon to commercialize its ID-TagTM Respiratory Viral Panel (RVP) in four Scandinavian countries.
|
|
September 11 2006
Warner To Buy MDS Pharma Services As part of a plan to grow from within, Warnex Inc. has struck an agreement in principle to buy MDS Pharma Services
|
|
September 08 2006
Private Placement Nets Lorus Nearly $2M Lorus Therapeutics Inc. has entered into an agreement with Technifund Inc. to issue five million common shares at $0.36 per share on a private placement basis, resulting in gross proceeds of $1.8 million
|
|
September 08 2006
Protox Lands Institutional Investor Vancouver-based Protox Therapeutics Inc. has a new institutional investor in B.C.-based Lions Liquidity Investment Fund, which is managed by Protox chairman Frank Holler.
|
|
September 05 2006
AnorMED Rejects Genzyme Takeover Bid Based on recommendations made by its Strategic Initiatives Committee, AnorMED Inc.'s board of directors has recommended that shareholders reject a hostile takeover bid made by Genzyme Corp.
|
|
August 22 2006
NHL Pairs With Natural Cold Remedy The National Hockey League (NHL) and the National Hockey League Players Association have jumped into the biotech game.
|
|
August 14 2006
Sandia and Monsanto Strike Deal Sandia National Laboratories and Monsanto Co. have signed a three-year research collaboration focused on biology and bioenergy.
|
|
August 10 2006
Public Offering Nets Nuvo $15M Nuvo Research Inc. recently received a $15-million boost through a public offering of 37,500,000 units at $0.40 per unit.
|
|
August 10 2006
Investors Place $12M in Plants Performance Plants Inc. has completed a new financing
round of $12 millionthe largest private investment in an agbiotech company in Canada. |
|
August 10 2006
MBI Signs Vancouver-based Med BioGene Inc. (MB) I has signed a letter of intent with the Ontario Institute for Cancer Research (OICR) (Toronto, ON) to acquire tumour tissue samples of confirmed lymphoma patients from the Ontario Tumour Bank. The bank is an initiative of the OICR.
|
|
August 10 2006
Cross-Atlantic Collaboration ProMetic BioSciences' U.K. Endeavour
British science is taking leading-edge academic research and using it to build a portfolio of commercial products and technologies that top pharmaceutical companies worldwide are applying to the field of human medicine |
|
August 09 2006
Ottawa Tech, Life Sciences Sectors Merge n an effort to gather more weight behind local life sciences and technology sectors, the Ottawa Life Sciences Council (OLSC) and the Ottawa Centre for Research and Innovation (OCRI) have merged forces.
|
|
August 09 2006
Biophage Raises Additional Private Funding Biophage Pharma Inc. has closed a third tranche of the private placement announced in April.
|
|
August 09 2006
Medical Mobile Medical Mobile, a French affiliate of Quebec City, QC-based Medical Intelligence Technologies Inc., has signed an agreement with Techniconsult Ingénierie (Marseille, France) and Hatos Consulting for the distribution of the Columba phone bracelet
|
|
August 09 2006
Inflazyme Pharmaceuticals Ltd and BioSeek Inc. Richmond, B.C.-based Inflazyme Pharmaceuticals Ltd. and BioSeek Inc. (Burlingame, CA) will collaborate on research following an agreement signed in June.
|
|
August 09 2006
Spectral Diagnostics Inc. Spectral Diagnostics Inc. (Toronto, ON) has signed a distribution agreement with Estor SpA (Pero, Italy) for the commercial sales of its sepsis test, the Endotoxin Activity AssayTM.
|
|
August 09 2006
Viropro Inc. Viropro Inc. (Montreal, QC) has signed a memorandum of understanding with BioChallenge (Tunis, Tunisia) to develop and produce several therapeutic proteins.
|
|
July 25 2006
Biovail Ends Cardiovascular Partnership Biovail Corp. (Mississauga, ON) and Athpharma Ltd. (Athlone, Ireland) have amicably terminated their joint-development agreement for four cardiovascular products.
|
|
July 10 2006
Biophage Enters Biosensor Agreement Biophage Pharma Inc. (Montreal, QC) has signed a memorandum of understanding with two U.S.-based companies for the development and manufacturing of next-generation PDS® biosensors.
|
|
July 05 2006
GenoLogics Life Sciences Partners With Geneva Bioinformatics GenoLogics Life Sciences Software Inc. (Victoria, BC) and Geneva Bioinformatics, (GeneBio) (Geneva, Switzerland) will be integrating GeneBios proteomics mass spectrometry (MS) data analysis platform, Phenyx, with GenoLogics' Proteus data management system
|
|
July 05 2006
Ondine Biopharma and UCL BioMedica Sign R&D Agreement In hopes of tackling antimicrobial resistance, Ondine Biopharma Corp. (Vancouver, BC) and UCL BioMedica (London, UK), a wholly owned subsidiary of University College London, have signed a multi-year R&D agreement.
|
|
July 05 2006
ProMetic Life Sciences And American Red Cross Sign Agreement Pathogen Removal and Diagnostic Technologies Inc.-a joint venture between ProMetic Life Sciences Inc. (Montreal, QC) and the American Red Cross (Washington, DC)-has signed a licensing agreement.
|
|
July 05 2006
Meridian Co. Signs Deal With Jang's & Parms Meridian Co. Ltd. (Seoul, Korea) has signed a preliminary distribution deal with Jang's & Parms Corp.
|
|
July 05 2006
Angiotech Acquires Quill Medical Angiotech Pharmaceuticals Inc. (Vancouver, BC) is expanding into a growing marketaesthetics and wound closure.
|
|
June 30 2006
Cytochroma Acquires Proventiv Markham, Ont.-based Cytochroma Inc. has acquired Proventiv Therapeutics (Madison, WI).
|
|
June 26 2006
Performance Plants Raises $12M Performance Plants Inc. (Kingston, ON) has raised $12 million in a recent round of financing.
|
|
June 05 2006
Cangene Signs $362M US Contract The U.S. Department of Health and Human Services (HHS) has awarded Cangene Corp. (Winnipeg, MB) a five-year development and supply contract worth $362 million US.
|
|
May 31 2006
Millipore Acquires Newport Bio Systems Billerca, Mass.-based Millipore Corp. has acquired Newport Bio Systems (Anderson, CA), a bioprocess consumable manufacturer.
|
|
May 31 2006
Sigma Expands Into China Sigma-Aldrich Corp. (St. Louis, MO) has established a wholly owned subsidiary, Sigma-Aldrich (Shanghai) Trading Co. and has acquired Beijing Superior Chemicals and Instruments Co. Ltd. (Beijing, China), expanding its presence in China.
|
|
May 31 2006
Bruker BioSciences Acquires Bruker Optics Bruker BioSciences Corp. (Billerica, MA) has acquired Bruker Optics Inc. (Billerica, MA), a privately held company that provides research, analytical and process analysis instruments based on Fourier transform infrared.
|
|
May 29 2006
PharmaGap to Sell Lead Candidate In keeping with last year's business strategy announcement, Ottawa-based PharmaGap Inc. is planning to sell or license its lead drug candidate, PhGalpha1.
|
|
May 19 2006
ConjuChem Raises $15.75M Montreal-based ConjuChem Inc. has closed a previously announced bought deal, generating gross proceeds of nearly $16 million.
|
|
May 15 2006
BioSyntech Raises $21M Laval, Que.-based BioSyntech Inc. recently closed the third tranche of a previously announced financing, bringing the transaction total to $21 million.
|
|
May 08 2006
Migenix Raises $8.8M Vancouver-based Migenix Inc. has raised $8.8 million through the sale of a partial royalty interest to U.S.-based investment funds.
|
|
April 30 2006
MethylGene Raises $20M MethylGene Inc. (Montreal, QC) intends to close a private placement that will garner the company a total of $20 million US.
|
|
April 24 2006
Tm Signs Distribution Agreement Toronto-based Tm Bioscience Corp. has signed its first regional distribution agreement for the companys ID-Tag Respiratory Viral Panel (RVP), used for detection of 20 viruses, including avian flu.
|
|
April 03 2006
Response Raises $12M, Appoints Directors Burnaby, B.C.-based biotechnology company Response Biomedical Corp. has closed two private placements, which raised a total of $12 million in gross proceeds.
|
|
March 27 2006
Theratechnologies Raises $20M Montreal, Que.-based Theratechnologies Inc. has raised more than $20 million in gross proceeds following the completion of its recent bought deal, which offered 10,500,000 common shares at a price of $1.95 per share.
|
|
March 23 2006
Ciphergen Pairs with Sanofi-Aventis in Biomarker Research Ciphergen Biosystems Inc. (Fremont, CA) and Sanofi-Aventis (Paris, France) have entered into a collaborative research agreement.
|
|
March 23 2006
Pall Teams With Biotrace on Environmental Products East Hills, N.Y.-based Pall Corp. has signed an agreement with Biotrace International (Bridgend, Wales), providing Pall with access to exclusive global marketing and distribution rights for Ascotec environmental air-monitoring products, used in pharmaceutical applications.
|
|
March 22 2006
PerkinElmer Partnership to Develop Diagnostic Tools PerkinElmer Inc. (Wellesley, MA) has signed a long-term licensing deal with Luminex® Corp. (Austin, TX) to develop diagnostic technologies.
|
|
March 22 2006
Sigma Enters RNAi Deal with Genospectra Sigma-Aldrich Corp. (St. Louis, MO) has signed several agreements with Fremont, Calif.-based Genospectra, as part of a deal that will expand Sigma's portfolio in the areas of RNA interference, gene expression and cell-based assays.
|
|
March 22 2006
Sandoz Canada Acquisition Complete Sandoz Canada Inc.'s (Boucheville, QC) acquisition of generic pharmaceutical company RhoxalPharma has been completed, with all RhoxalPharma assets being transferred to Sandoz Canada.
|
|
March 22 2006
PainCeptor Receives $480,000 for Drug Development Program The National Research Council of Canada's (NRC) (Ottawa, ON) Industrial Research Assistance Program has granted $480,000 to PainCeptor Pharma Corp. (Montreal, QC) in support of a development program for pain therapeutics.
|
|
March 22 2006
Montreal Hospital Adopts Reagents in Cystic Fibrosis Test The Montreal Children's Hospital (Montreal, QC) has selected Tm Bioscience Corp.'s (Toronto, ON) Tag-It reagents for use in a cystic fibrosis testing program.
|
|
March 07 2006
Injunction Filed Against QLT - Company To Appeal A U.S. court has filed an injunction against QLT Inc. (Vancouver, BC) and its partner Sanofi-Aventis (Paris, France), preventing the companies from manufacturing or selling prostate cancer drug Eligard until May 1.
|
|
March 02 2006
Angiotech Acquires U.S. Device Company Vancouver-based Angiotech Pharmaceuticals Inc. has entered into a major deal, acquiring American Medical Instruments Holdings Inc. (AMI) (Lake Forest, IL) for approximately $900 million in cash.
|
|
March 02 2006
$6M in Financing For Medical Ventures Medical Ventures Corp. (Richmond, BC) will receive more than $6 million in financing after striking a deal with Sprott Securities Inc. (Toronto, ON).
|
|
March 02 2006
Microbix Takes Over ThromboClear Commercialization Microbix Biosystems Inc. (Toronto, ON) and Genpharm Inc. (Toronto, ON) have renegotiated their licensing agreement to reflect recent changes in their plan to commercialize ThromboClear, a urokinase product.
|
|
February 20 2006
YM BioSciences Receives Fast Track Status, $40M in Financing Missisauga, Ont.-based YM BioSciences Inc. has received fast track status from the U.S.
|
|
February 13 2006
Transition Increase Stake in Ellipsis Toronto-based Transition Therapeutics Inc. has acquired of an additional 1.5 million common shares of Ellipsis Neurotherapeutics Inc. (Toronto, ON).
|
|
February 06 2006
BioMS Increases Stake in BioCyDex Exercising a previously held option, Edmonton-based multiple sclerosis company BioMS Medical Corp. has purchased additional equity in BioCyDex Inc.
|
|
February 06 2006
Migenix Inc. Has entered into a license agreement with Philadelphia, Penn.-based Cutanea Life Sciences Inc. to develop and commercialize MX-594AN, an antimicrobial cationic peptide currently in development as a topical treatment for mild to moderate acne vulgaris.
|
|
February 06 2006
Nanogen Inc. Has signed a definitive agreement with Toronto-based Spectral Diagnostics Inc. whereby Nanogen will acquire Spectral's rapid cardiac immunoassay test business.
|
|
February 06 2006
Montreal-based Magistral Biotech Inc. Has reached an agreement in principle with Diversified Natural Products Inc. (DNP) (New York, NY) and the University of Sherbrooke (Sherbrooke, QC) allowing for DNP's acquisition of all of Magistral's cholesterol lowering-related assets.
|
|
February 06 2006
Burnaby, B.C.-based Chromos Molecular Systems Inc. Has expanded its collaboration with New York, N.Y.-based Pfizer Inc., wherein Chromos will use its ACE System to develop a cell line for a Pfizer protein product candidate.
|
|
February 05 2006
CV Technologies Receives Conditional TSX Listing Edmonton-based CV Technologies Inc.'s application for listing on the Toronto Stock Exchange (TSX) (Toronto, ON) has been conditionally approved.
|
|
January 29 2006
Biomira Announces $16.1M Financing Edmonton-based Biomira Inc. has announced a financing arrangement worth approximately $16.1 million US with New York, N.Y.-based investment banking firm Rodman & Renshaw.
|
|
January 23 2006
Procyon Deal Leads to New Company Montreal-based Procyon Biopharma Inc. has signed a definitive agreement to acquire Cellpep SA (Paris, France), a private company that develops therapeutics for oncology and infectious diseases.
|
|
January 16 2006
Vertex, CFFT Extend Research Agreement Cambridge, Mass.-based Vertex Pharmaceuticals Inc. has extended its existing research collaboration with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) (Bethesda, MD).
|
|
January 09 2006
Applied Biosystems Extends Japanese Deal Applied Biosystems Group (Foster City, CA) and Hitachi High-Technologies Corp. (Tokyo, Japan) have signed an exclusive development and commercialization deal in an effort to advance capillary electrophoresis (CE)-based DNA analysis technologies.
|
|
January 01 2006
Partnership Aims to Improve Edmonton Health Sciences Three Edmonton, Alta.-based organizations have joined forces in an effort to make the city a Canadian and international leader in the health sciences sector.
|
|
January 01 2006
Viron Receives French Honour London, Ont.-based Viron Therapeutics Inc. has been awarded the Prix Galien Canada in biotechnology.
|
|
January 01 2006
Maxxam Analytics Partners with Fisher Scientific Maxxam Analytics Inc. (Mississauga, ON) announced a significant new partnership with Fisher Scientific Canada (Ottawa, ON).
|
|
January 01 2006
$10M in Financing for MedMira Diagnostic test developer MedMira Inc. (Halifax, NS) has closed an equity line financing, generating $10 million in funds.
|
|
January 01 2006
Chromos to Acquire U.S.-based Targeted Molecules Shareholders of Chromos Molecular Systems Inc. (Burnaby, BC) have approved the acquisition of San Diego, Calif.-based Targeted Molecules Corp., a company focused on the discovery and development of Selective Adhesion Molecule Inhibitors, a class of novel antibody therapeutics.
|
|
January 01 2006
BHRC Program Pays Employers Job seekers and companies alike will benefit from a program offered by the Biotechnology and Human Resource Council (BHRC) (Ottawa, ON).
|
|
January 01 2006
NutriCorp International NutriCorp International (Windsor, ON), a division of nutraceutical supplement manufacturer Jamieson Laboratories (Toronto, ON), has signed an exclusive manufacturing deal with BioEnvelop Technologies Corp. (Laval, QC) for the development of nutraceutical film products.
|
|
January 01 2006
Biovail Corp. A subsidiary of Biovail Corp. (Mississauga, ON) has entered into a supply agreement with Ortho-McNeil Inc. (Titusville, NJ) for the marketing and distribution of Ultram® ER and Ultram ODT, the companys extended-release and orally disintegrating formulations, respectively.
|
|
January 01 2006
Generex Biotechnology Corp |
|
January 01 2006
QSV Biologics Ltd. |
|
January 01 2006
Ottawa, Ont.-based PharmaGap Inc. |
|
December 07 2005
Glaxo Acquisition of ID Biomedical Approved The British Columbia Supreme Court has approved GlaxoSmithKlines (GSK) (Middlesex, UK) bid to acquire Vancouver, B.C.-based ID Biomedical Corp.
|
|
December 01 2005
Theramed Corp A wholly owned subsidiary of Meta Health Services Inc. (Mississauga, ON), has entered into a sales and distribution agreement with Mississauga, Ont.-based AstraZeneca Canada Inc.
|
|
October 25 2005
Cardiome Completes Artesian Acquisition Vancouver, B.C.based Cardiome Pharma Corp. has completed its previously announced acquisition of Gaithersburg, Md.-based Artesian Therapeutics Inc.
|
|
October 18 2005
Bioniche Considers Private Placement Belleville, Ont.-based Bioniche Life Sciences Inc. has signed a non-binding term sheet with an institutional investor in anticipation of a potential private financing.
|
|
October 05 2005
Biogen Idec Sponsors Biotech Teaching Award Canadian bioscience teachers will now be recognized for their efforts, thanks to a new award introduced by industry association BIOTECanada (Ottawa, ON) and Biogen Idec Canada (Mississauga, ON).
|
|
October 04 2005
Labopharm, GSK Partner for Latin American Tramadol Market Laval, Que.-based Labopharm Inc. has entered into a licensing and distribution agreement with GlaxoSmithKline (GSK) (Middlesex, U.K.) for its once-daily formulation of analgesic tramadol.
|
|
September 13 2005
Victhom Enters into Long-term Agreement with Icelandic Firm Quebec City, Que.-based Victhom Human Bionics Inc. has signed a development and commercialization agreement with Reykjavik, Iceland-based Ossur hf.
|
|
September 06 2005
Millenium Biologix Signs License Agreement with MIT Kingston, Ont.-based Millenium Biologix Corp. has entered into an exclusive license agreement with the Massachusetts Institute of Technology (MIT) (Cambridge, MA) in an effort to enhance the company's cartilage repair regeneration product.
|
|
August 29 2005
Millenia Hope, Coca-Cola Collaborate on Malaria Study Westmount, Que.-based Millenia Hope Inc. has found an unlikely partner for testing its malaria treatment, MMH Malarex(tm) / MMH(tm) 18.
|
|
August 19 2005
Response Biomedical Receives Largest-ever Order for Biodefence System The Atlanta Fire Department (Atlanta, GA) is the latest in a series of U.S. organizations to order Response Biomedical Corp.'s (Burnaby, BC) popular RAMP® Biodetection System, placing the largest-ever order for the product.
|
|
August 15 2005
Allon Therapeutics Plans $6.2M Financing Vancouver, B.C.-based Allon Therapeutics Inc. has announced a $6.2-million private placement to a group of largely institutional investors.
|
|
August 08 2005
Biotech Finance: A "Plug" for SPARCs By Joseph Garcia and Jeremy Feist Obtaining financing is one of the greatest challenges facing many biotech companies in Canada today. Ernst & Young LLP (Toronto, ON) recently reported that 56 per cent of Canadian public biotech companies have less than two years of cash.
|
|
July 25 2005
Biorem to Run North America's Largest Pilot Odour-control Project Guelph, Ont.-based Biorem Technologies Inc. has been chosen to undertake a pilot odour-control study for the City of Toronto (Toronto, ON).
|
|
July 12 2005
Biorem Acquires Biocube Assets Guelph, Ont.-based Biorem Inc. has successfully acquired the assets of Victor, N.Y.-based Biocube LLC.
|
|
June 28 2005
US Acquisition for Medical Facilities Corp. Medical Facilities Corp. (MFC) (Toronto, ON) has completed the acquisition of a 51-per-cent interest in the Oklahoma Spine Hospital LLC (OSH) (Oklahoma City, OK).
|
|
June 13 2005
Supply Agreement for Millipore and Quantum Dot Millipore Corp. (Billerica, MA) and Quantum Dot Corp. (QDC) (Hayward, CA) have entered into a supply agreement regarding Millipore's low background fluorescence membrane.
|
|
June 07 2005
Medicago and InterveXion Start Antibody-based Alliance Ste-Foy, Que.-based Medicago Inc. has announced the creation of a multi-year alliance with Vacaville, Calif.-based drug-development company InterveXion Therapeutics LLC.
|
|
May 25 2005
BioAxone Announces $12M Investment Montreal, Que.-based neuroscience company BioAxone Therapeutic Inc. has announced the closing of a $12.15 million second-round investment.
|
|
March 28 2005
Cardiome Pharma Completes Public Offering Vancouver, B.C.-based Cardiome Pharma Corp. has completed a public offering of 8.5 million common shares sold for $6 US per share, and resulting in gross proceeds of $51 million US.
|
|
March 22 2005
ChondroGene Receives NRC Funding for Osteoarthritis Test The National Research Council of Canada's (Ottawa, ON) Industrial Research Assistance Program has made a contribution to Toronto, Ont.-based ChondroGene Ltd. to aid in development of the company's blood-based molecular diagnostic assay.
|
|
March 15 2005
Nexia to Sell Protexia Assets Following recent shareholder approval, Nexia Biotechnologies Inc. (Vaudreuil-Dorion, QC) will be selling nearly all of its operations and assets relating to Protexia® to a wholly owned subsidiary of PharmAthene Inc. (Annapolis, MD).
|
|
March 07 2005
Procyon, Medicorp Enter Into Agreement Dorval, Que.-based Procyon Biopharma Inc. has entered into an agreement granting exclusive worldwide rights to Medicorp Inc. (Montreal, QC) to develop, manufacture and commercialize Procyon's PSP94-based test kits for research purposes.
|
|
February 14 2005
Scantox Acquired by Lab International Laval, Que.-based LAB International Inc. has acquired Scandinavian non-clinical contract research organization Scantox (Ejby, Denmark) for approximately $6.1 million.
|
|
January 31 2005
Cipher Pharmaceuticals Sells Research Services Business Mississauga, Ont.-based Cipher Pharmaceuticals Inc. has completed a deal to sell its research services business, Pharma Medica Research Inc. (Mississauga, ON), which currently runs the business.
|
|
January 13 2005
IPO Final Prospectus Filed by Stem Cell Therapeutics Biotechnology firm Stem Cell Therapeutics Corp. (Calgary, AB) filed a final prospectus late last December for an initial public offering of its common shares.
|
|
January 10 2005
AEterna Zentaris Acquires U.S. Biopharm Company Quebec City, Que.-based AEterna Zentaris Inc. has acquired the privately held biopharmaceutical firm Echelon Biosciences Inc. (Salt Lake City, UT).
|
|
November 20 2004
Dimethaid Closes $11.2M Financing Pharmaceutical firm Dimethaid Research Inc. (Toronto, ON) has closed a financing that raised $11.2 million in net proceeds.
|
|
September 27 2004
Ventures West Closes $250M Funding Round One of Canada's largest privately owned venture capital companies has closed its eighth venture capital fund, worth $250 million.
|
|
July 19 2004
YM BioSciences and CancerVax Enter Development Deal YM BioSciences Inc. (Mississauga, ON) has entered into a development agreement with CancerVax Corp. (San Diego, CA) for two active immunotherapeutics that were formerly licensed to YM BioSciences by the Center of Molecular Immunology (CIM) (Havana, Cuba).
|
|
June 14 2004
EquiTech Closes Private Placement Edmonton, Alta.-based EquiTech Corp. has completed a private placement totalling $500,000.
|
|
May 17 2004
Warnex Signs Deal with Turkey Processor Warnex Inc. (Laval, QC) has signed a three-year agreement with one of the world's largest turkey processing plants, Carolina Turkeys (Mt. Olive, NC), for the use of its Genevision(tm) technology.
|
|
May 03 2004
Canada Foundation for Innovation Provides $29.9M in University Funding Memory and neuroplasticity, ultrafast light manipulation and gene regulatory networks in early T-cell development - what do these things have in common?
|
|
April 19 2004
Proposed Venture Capital Merger Two Canadian venture capital firms may be joining forces. Pinetree Capital Corp. and Genevest Inc., both based in Toronto, Ont., have announced a proposed merger.
|
|
April 12 2004
QLT Acquires Kinetek Pharmaceuticals QLT Inc. (Vancouver, BC) has acquired Kinetek Pharmaceuticals Inc. (Vancouver, BC), a biotechnology company with which QLT has collaborated on a research and early development program since June 2001.
|
|
April 05 2004
Draxis Health Raises $20M Draxis Health Inc. (Mississauga, ON) has agreed to sell 3,053,436 units to a syndicate of underwriters led by Desjardins Securities (Montreal, QC). Each unit, costing $6.55, consists of one common share and one-half of one share purchase warrant.
|
|
March 29 2004
MDS Diagnostic Services Sells Two U.S. Labs MDS Diagnostic Services - part of MDS Inc. (Toronto, ON) - has sold two of its U.S. labs to Laboratory Corp. of America® Holdings (LabCorp®) (Burlington, NC). Financial terms of the asset purchase transaction were not disclosed.
|
